University of South Florida

Digital Commons @ University of South Florida
USF Tampa Graduate Theses and Dissertations

USF Graduate Theses and Dissertations

March 2022

Phenotypic Variability in iPSC-Induced Cardiomyocytes and
Cardiac Fibroblasts Carrying Diverse LMNA Mutations
Jiajia Yang
University of South Florida

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the Physiology Commons

Scholar Commons Citation
Yang, Jiajia, "Phenotypic Variability in iPSC-Induced Cardiomyocytes and Cardiac Fibroblasts Carrying
Diverse LMNA Mutations" (2022). USF Tampa Graduate Theses and Dissertations.
https://digitalcommons.usf.edu/etd/9504

This Dissertation is brought to you for free and open access by the USF Graduate Theses and Dissertations at
Digital Commons @ University of South Florida. It has been accepted for inclusion in USF Tampa Graduate Theses
and Dissertations by an authorized administrator of Digital Commons @ University of South Florida. For more
information, please contact scholarcommons@usf.edu.

Phenotypic Variability in iPSC-Induced Cardiomyocytes and Cardiac Fibroblasts
Carrying Diverse LMNA Mutations

by

Jiajia Yang

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Molecular Pharmacology and Physiology
College of Medicine
University of South Florida

Major Professor: Thomas McDonald, M.D.
Derek Wildman, Ph.D.
Sami Noujaim, Ph.D.
Thomas Taylor-Clark, Ph.D.

Date of Approval:
March 21, 2022

Keywords: Lamin A/C, dilated cardiomyopathy, connexin 43, extracellular matrix
Copyright © 2022, Jiajia Yang

ACKNOWLEDGEMENTS
First and foremost, I owe a debt of gratitude to Dr. Thomas McDonald, not only
for introducing me to the world of patient-specific induced pluripotent stem cells and
cardiac electrophysiology, but also for his tireless supervision in lab and enthusiastic
guidance at his Cardiogenetic Clinic. The past 5 years of my PhD under his mentorship
have been most challenging, rewarding, and enjoyable. I can see myself growing
tremendously as a scientist, a medical graduate but especially as a person. His kind
heart, optimism, thoughtfulness and sense of humor are a lifelong inspiration to me. I
simply cannot ask for a better mentor, and I could not be more grateful for his
unparalleled support and much-needed help with my future career development.
I would like to thank my committee members, Drs. Sami Noujaim, Thomas
Taylor-Clark and Derek Wildman, brilliant scientists who have offered me invaluable
feedback and substantial support at the enlightening discussions and meetings
throughout my project. I also wish to express my gratefulness to the administrative staff
of my PhD office, Meagan Eastman and Shonique Edwards, and concentration
coordinator Dr. Kay-Pong Yip and Dr. Jerome Breslin for making my PhD curriculum
and procedures such a smooth and pleasant journey.
I have had the fortune to enjoy the company of some great friends and
colleagues over the course of this project, Mariana Burgos Angulo, Dr. Mariana

Argenziano, Dr. Alexander Bertalovitz, and Dr. Maliheh Najari Beidokhti.
Specifically, I would like to acknowledge the contributions of Dr. Argenziano to cardiac
fibroblast generation and calcium imaging.
I owe a lot to my dearest friends, Dr. Xiaoyuan Yang, Dr. Yiting Li, Dr. Jianxiang
Xue, Mariana Burgos Angulo and Dr. Li-Min Ting. It is through their advice and
encouragement, moral support and precious friendship that I can survive and thrive my
PhD.
My deepest and sincerest appreciation goes to my parents and siblings for their
continuous and unconditional love and support. Knowing that they will always be there
for me, I can focus on and pursue my career goals wholeheartedly wherever I go.
Finally and perhaps most importantly, I would like to extend my thankfulness to
those patients on the Modeling Cardiogenetic Conditions in Cell Culture program who
donated their blood samples to science, without whom none of this work would have
been possible.

TABLE OF CONTENTS
List of Tables ··································································································ii
List of Figures ································································································ iii
Abstract ········································································································ vi
Chapter One — Introduction and Background······················································· 1
Dilated cardiomyopathy (DCM) ································································· 1
LMNA ·································································································· 5
Induced pluripotent stem cells (iPSC) ·······················································11
Hypothesis ··························································································15
Chapter Two — Cellular phenotypic alterations in LMNA-iCMs ·······························19
Introduction ·························································································19
Methods······························································································20
Results ·······························································································34
Discussion···························································································57
Chapter Three — Contribution of cardiac fibroblast to LMNA-related
cardiomyopathy ························································································61
Introduction ·························································································61
Methods······························································································62
Results ·······························································································67
Discussion···························································································80
Chapter Four — Conclusions and Perspectives ···················································85
Chapter Five — Use of human iPSC-derived cardiomyocyte models to study the
cardiopathogenesis of the protozoan parasite, Toxoplasma gondii ······················92
Introduction ·························································································92
Methods······························································································93
Results ·······························································································94
Discussion and future directions ···························································· 104
References ································································································· 105
Appendix I — List of Abbreviations ·································································· 122

i

LIST OF TABLES
Table 1:

Present studies on LMNA related cardiomyopathy ·····························14

Table 2:

Clinical characteristics of subjects ···················································21

Table 3:

Antibodies used in this study ··························································27

Table 4:

Phenotype comparison of iCMs carrying different LMNA mutations ·······86

Table 5:

Phenotype comparison of iCFs carrying different LMNA mutations ········87

ii

LIST OF FIGURES
Figure 1:

Etiologies of dilated cardiomyopathy ················································· 2

Figure 2:

Schematic structure and function of lamin A/C ···································· 7

Figure 3:

Central hypothesis ·······································································16

Figure 4:

Differentiation and characterization of induced pluripotent stem cell
(iPSC)-derived cardiomyocytes (iCMs) ·············································36

Figure 5:

Variable levels of lamin A/C, extracellular signal-regulated kinase
(ERK) pathway hyperactivation, and cleaved caspase-3 in different
LMNA-iCMs ················································································38

Figure 6:

Characterization of lamin A/C nuclear morphology and sarcomere
structure in iCMs ·········································································39

Figure 7:

Analysis of calcium handling in all iCMs ···········································41

Figure 8:

Analysis of electrophysiological characteristics on micro electrode
array in all iPSC-CMs ···································································42

Figure 9:

Analysis of ion channel levels in iCMs ··············································43

Figure 10:

Comparison of pharmacological treatment on targeted pathways
affected by laminopathy ································································45

Figure 11:

Potential therapeutic target investigation in R377H-iCFs······················46

Figure 12:

Nuclear morphology investigation in R377H-iCFs following
treatment with selumetinib, lovastatin, ARRY797, SP600125, and
everolimus for 3 weeks ·································································47

Figure 13:

3D PCA plot showing clustering of iCM replicates ······························48

Figure 14:

Volcano plot representing differential transcriptome of LMNA
myocytes vs control······································································50

Figure 15:

Heat map representing differential transcriptome of LMNA iCMs vs
three controls ··············································································51
iii

Figure 16:

Venn diagram analyses of iCMs comparing the shared and unique
DEGs of five different LMNA variants relative to controls ·····················53

Figure 17:

Gene expression cluster analysis of DEGs in iCMs showing top 5
pathways ···················································································55

Figure 18:

Differentiation and characterization of iPSC-derived cardiac
fibroblasts (iCFs) ·········································································63

Figure 19:

Variable levels of lamin A/C, extracellular signal-regulated kinase
(ERK) pathway hyperactivation, and cleaved caspase-3 in different
LMNA-iCFs ················································································64

Figure 20:

Characterization of lamin A/C nuclear morphology in iCFs ···················66

Figure 21:

Reduced migration rate in LMNA mutated-iCFs ·································67

Figure 22:

Analysis of connexin 43 ion channel levels in iCFs ·····························68

Figure 23:

Analysis of coculture of iCMs and iCFs ············································70

Figure 24:

3D PCA plot showing clustering of iCF replicates ·······························71

Figure 25:

Volcano plot representing differential transcriptome of different
LMNA-iCFs vs controls ·································································73

Figure 26:

Heat map representing differential transcriptome of LMNA mutated
iCFs vs controls···········································································75

Figure 27:

Venn diagram analyses of iCFs comparing the shared and unique
DEGs of five different LMNA variants relative to controls ·····················76

Figure 28:

Gene expression cluster analysis of DEGs from iCFs showing top 5
pathways ···················································································78

Figure 29:

Heat map of dysregulated pathways compared across the different
LMNA-iCMs ················································································88

Figure 30:

Heat map of dysregulated pathways compared across the different
LMNA-iCFs ················································································88

Figure 31:

Flow cytometry showing percentage of tachyzoite and bradyzoite
formation in iPSC-CM, iPSC-CF and HFF infected with T. gondii
TypeI/III EGS strain for 24 hours and 72 hours ··································95
iv

Figure 32:

PCA plot showing clustering of iPSC induced cells infected with T.
gondii EGS strain·········································································96

Figure 33:

Volcano plot representing differential transcriptome of iCMs
infected with T. gondii EGS strain for 24 hours and 72 hours vs
uninfected iCMs ··········································································97

Figure 34:

Heat map representing differential transcriptome of iCMs infected
with T. gondii EGS strain for 24 hours and 72 hours vs uninfected
iCMs ·························································································98

Figure 35:

Gene expression cluster analysis of DEGs from iCMs infected with
T. gondii EGS strain for 24 hours and 72 hours vs uninfected iCMs ····· 100

Figure 36:

Volcano plot representing differential transcriptome of iCFs infected
with T. gondii EGS strain for 24 hours and 72 hours vs uninfected
iCFs ························································································ 101

Figure 37:

Heat map representing differential transcriptome of iCFs infected
with T. gondii EGS strain for 24 hours and 72 hours vs uninfected
iCFs ························································································ 101

Figure 38:

Gene expression cluster analysis of DEGs from iCFs infected with
T. gondii EGS strain for 24 hours and 72 hours vs uninfected iCFs ······ 103

v

ABSTRACT
Mutations in the LMNA gene (encoding lamin A/C) are the second most common
cause of familial arrhythmogenic cardiomyopathy. Diverse LMNA variants in
cardiomyocytes have been associated with cardiac phenotypes. Moreover, cardiac
fibroblasts make up a large fraction of the myocardium's non-myocyte component,
intrinsically linked to extracellular matrix synthesis and turnover as well as secreting
large amounts of bioactive metabolites. However, our understanding of how different
mutation sites and the non-myocyte niche mediate cardiomyocyte function is limited. To
fill this gap, in this thesis I investigated the hypothesis that variable LMNA mutations
have significant effects on the genetic, structure and electrophysiological properties of
cardiomyocytes and cardiac fibroblasts.
I differentiated iPSC-derived cardiomyocytes (iCMs) and cardiac fibroblasts
(iCFs) from seven different patients carrying LMNA mutation: M1I, R216C/R399H,
R216C-male (R216C.m), R216C-female (R216C.f), R335Q, R377H and R541C. LMNA
expression and extracellular signal-regulated kinase pathway activation were perturbed
to varying degrees in both iCMs and iCFs from the different lines. Enhanced apoptosis
occurred in iCMs but not in iCFs. Markedly diverse irregularities of nuclear membrane
morphology were present in iCFs but not iCMs, while iCMs demonstrated variable
sarcomere disarray. Heterogenous electrophysiological aberrations assayed by calcium
indicator imaging and multi-electrode array suggest differing substrates for arrhythmias
that were accompanied by variable ion channel gene expression in the iCMs. Direct
vi

contact iCM-iCF co-cultures suggest enhancement of the LMNA mutation effects on
electrophysiological function exerted by iCFs, possibly linked to the disturbed location
and quantity of connexin 43. RNA sequencing demonstrated remarkable enrichment
terms associated with extracellular matrix constituents and organization both in iCMs
and iCFs derived from various LMNA mutation carriers.
This work supports the growing understanding of the use of patient-specific
iPSCs in modeling and deciphering cardiovascular diseases. Cardiac fibroblasts play a
fundamental role in supporting and regulating cardiomyocyte electrophysiology function.
Given that the molecular pathways to disease differ with specific mutations, one
therapeutic option is not likely to suit every patient unless the specific genotype is
considered (i.e., one size will not fit all).
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CHAPTER ONE
INTRODUCTION AND BACKGROUND
Dilated cardiomyopathy (DCM)
Familial cardiomyopathy (CM) is a common Mendelian inherited heart condition
that can affect people of any age. Hypertrophic cardiomyopathy (HCM) prevalence is as
high as 1 in 200-250 in the general population. Dilated cardiomyopathy (DCM) and
arrhythmogenic cardiomyopathy (ACM) are in the range of 1:250 and 1:1250,
respectively (Hershberger, Hedges, & Morales, 2013; Peters, Kumar, Elliott, Kalman, &
Fatkin, 2019). Non-ischemic DCM is characterized by dilation of the left ventricle,
eventual thinning of the ventricular wall, and systolic dysfunction. It is among the most
prevalent causes of heart failure with eventual progression to early death, left ventricular
assist device implantation, or cardiac transplantation (Japp, Gulati, Cook, Cowie, &
Prasad, 2016).
DCM is caused by either acquired (for example coronary ischemia, infective
organism, medications, toxins, alcohol, nutritional deficits, autoimmune, metabolic,
endocrine, and peripartum diseases) or inherited factors (Figure 1) (Weintraub,
Semsarian, & Macdonald, 2017). Hereditary DCM accounts for around 25–35 percent of
those affected by DCM, arising from mutations in genes encoding cytoskeletal proteins
such as α-cardiac actin, titin, desmin, and the nuclear lamin A and C (LMNA) (Reichart,
Magnussen, Zeller, & Blankenberg, 2019). Clinical manifestations of DCM are similar to
1

that of other causes of heart failure including fatigue, leg swelling, shortness of breath,
chest pain or fainting, reduced exercise capability or arrhythmias (particularly with
LMNA mutations), thromboembolic events and sudden cardiac death (Abelmann &
Lorell, 1989).

Figure 1. Etiologies of dilated cardiomyopathy (adapted from Brayson et al., Nucleus.
2017)

Regarding the evaluation of DCM, it is important to exclude the secondary
causes before considering the hereditary or genetic forms. Laboratory testing for
secondary causes of DCM consists of thyroid function tests, HIV serology, electrolytes,
2

and iron studies (to exclude hemochromatosis). It is recommended to check urine
toxicology and alcohol level for suspicion of substance abuse. For patients with
uncertain history of coronary artery disease, coronary angiography is suggested to
investigate the coronary structure and rule out an obscure ischemic disease that causes
DCM. Chest X-ray might demonstrate signs of cardiomegaly, pulmonary effusions, and
venous congestion. Electrocardiogram (ECG) may be normal but may reveal
nonspecific ST segment and T wave aberrations, low QRS voltage, pseudo-infarct Qwaves, and cardiac conduction abnormalities. Echocardiography is critical in confirming
DCM and characterizing ventricular size, function, and any accompanying valvular
defects (Mahmaljy, Yelamanchili, & Singhal, 2022). The recent development of cardiac
magnetic resonance (CMR) and late gadolinium enhancement (LGE) techniques has
allowed detailed analyses of cardiac function and tissue characterization in both
ischemic and non-ischemic cardiomyopathies (Raman, Sparks, Baker, McCarthy, &
Wooley, 2007; Satoh et al., 2014). Histopathological proof by endomyocardial biopsy
(EMB) is valuable in ruling out cardiac amyloidosis or sarcoidosis (Aghdassi & Gupta,
2019).
In addition to identifying and managing any possible reversible causes, current
clinical management strategies for hereditary DCM are like other cardiomyopathies or
heart failure. Since DCM usually gives rise to decreased contractility, the first-line
approach for people with DCM is to alleviate heart failure. Standard pharmaceutical
therapies include ACE inhibitors, angiotensin receptor antagonists and β-blockers.
Angiotensin receptor inhibitor and neprilysin inhibitor combination have shown benefits
in the reduction of total mortality and hospital admissions in comparison with ACE
3

inhibitors. In combination with ACE inhibitors and β-blockers, mineralocorticoid receptor
antagonists and inhibitors improve survival or hospital admission. Together, these
pharmacological interventions constitute what is now known as Guidelines-Directed
Medical Therapy (GDMT). To avoid life-threatening arrhythmias, cardiac
resynchronization therapy (CRT) and implantable cardioverter–defibrillators (ICD) may
be indicated (Schultheiss et al., 2019).
Patients with nonischemic DCM should be considered for molecular genetic
testing regardless of their age. It is recommended to adopt a systematic method to
approach these patients, which includes holistic family history, a comprehensive
assessment of the clinical manifestations of the proband and family members at risk, a
referral to a genetic specialist, and genetic testing (next-generation sequencing with
targeted gene panel, whole-exome, whole-genome sequencing) to validate diagnosis
and guide management strategies (Hershberger et al., 2018).
Overall, hereditary cardiomyopathy due to genetic mutations comprises a
progressive form of familial heart disease that is common but has eluded preventative
therapeutic measures. Genetic testing is becoming an integral part of an evaluation of
suspected familial cardiomyopathy patients and causative genetic variants are found in
a significant proportion of those screened. This has enabled Personalized or Precision
Diagnostics to be applied to entire families of the proband.
LMNA
Lamins are type V intermediate filament proteins and it is the major structural
components of the nucleus, called nuclear lamina (Crasto, My, & Di Pasquale, 2020;
4

Dittmer & Misteli, 2011). Lamins are composed of two major categories: A- and B-types.
LMNA gene is located at chromosome 1q21.1-21.2 and is consisted of 12 exons
spanning around 25 kb (Lin & Worman, 1993). It encodes A-type lamins including
alternative splice variants lamins A and C. On the other hand, B-type lamin is another
major type, including lamins B1 and B2. They are products of two separate genes,
LMNB1 and LMNB2.
The structural components (Figure 2A) of the lamin A (664 amino acids) and
lamin C (572 amino acids) proteins are a globular N-terminal head domain, a central
coiled-coil rod domain involved in protein dimerization, and a C-terminal tail domain that
contains an immunoglobulin-like domain where numerous posttranslational
modifications take place. Posttranslational modification influences lamin polymerization
and lamin interactions with associated proteins and is particularly crucial to generate
mature lamin A from prelamin A. Prelamin A contains a CAAX motif (C = cysteine, A =
aliphatic, X = any residue) which acts as a site for subsequent posttranslational
modifications and undergoes CAAX processing. This series of three reactions includes
farnesylation of cysteine, proteolytic removal of the AAX residues, and carboxyl
methylation of the farnesylated cysteine by isoprenylcysteine methyltransferase (Spear
et al., 2018). The remaining C-terminal 15 amino acids are removed in a second
cleavage by ZMPSTE24, resulting in a short peptide and mature lamin A (Herrmann &
Aebi, 2004). The distinction between lamins A and C is found in the C-terminal tail
region. Lamin C lacks the 98 amino acids located at the C-terminus of prelamin A
(thereby missing the CAAXmotif) (Donnaloja, Carnevali, Jacchetti, & Raimondi, 2020).

5

Lamin A/C has a wide variety of functions (Figure 2B). First of all, lamins are
attached to the internal face of the inner nuclear membrane, providing a platform for the
binding of proteins and chromatin and playing mechanical supporting roles in cells and
during mitosis. LMNA mediates nucleo-cytoskeletal connections by the so-called Linker
of Nucleoskeleton and Cytoskeleton (LINC) complex, composed of lamin partner
nuclear envelope proteins emerin, SUN1, SUN2, and nesprins (Crisp et al., 2006). By
breaking the mechanical link between the cytoskeleton and the nucleus, LMNA
mutations may enhance nuclear instability and, as a result, increase vulnerability to
mechanical stress, such as skeletal and cardiac muscle. Moreover, by engaging
scaffold/matrix attachment sites, lamins are essential in transcription, DNA replication,
chromosome condensing, and chromatin arrangement. Lamin A/C facilitates chromatin
organization and interacts with chromatin by means of histones and/or chromatinassociated proteins. Lamin-A-associated domains (LADs) are genomic areas that bind
with lamins. Lamin A/C is also involved in DNA repair. For example, cells from
Hutchinson-Gilford progeria syndrome (HGPS) patients showed a lag in the mobilization
of the repair factor p53-binding protein (53BP1) to damaged DNA locations (Liu et al.,
2005). LMNA also plays a role as a transcription regulator. Nuclear lamins can either
interact directly with chromatin or sequester transcriptional regulators at the nuclear
margin to affect gene expression. Furthermore, LMNA is essential in mediating the
cellular signaling pathway involved in cell growth, survival, migration, and differentiation,
such as mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin
(mTOR) pathways (Dechat et al., 2008; Gruenbaum, Margalit, Goldman, Shumaker, &
Wilson, 2005).
6

Figure 2. Schematic structure and function of lamin A/C. (A) Protein domains are
displayed color-coded corresponding to the exons. The heterozygous LMNA variants
recruited in this study are shown in yellow boxes. NLS, nuclear localization signal. (B) A
model unifying the mechanical and gene expression hypothesis underlying the
mechanisms of LMNA cardiomyopathy.

Unlike B-type lamins, the expression of A-type lamins is temporally regulated
during embryogenesis and is most highly expressed in differentiated cells (Butin-Israeli,
Adam, Goldman, & Goldman, 2012). Laminopathies are clinical disorders caused by
7

various mutations in LMNA, that disrupt posttranslational modifications and influence
the function of lamins. Currently, laminopathies can be categorized based on the
affected tissue: striated muscles (muscular dystrophy, cardiomyopathy), adipose tissue
(lipodystrophy), nervous system, and accelerated aging syndrome (HGPS). LMNA can
cause multisystem disorder or tissue-specific disorder (Broers, Ramaekers, Bonne,
Yaou, & Hutchison, 2006; Worman & Bonne, 2007). LMNA related cardiomyopathy is
an autosomal dominant disorder (Fatkin et al., 1999).
LMNA mutations now account for 6–8% of dilated cardiomyopathy with
conduction deficiency, which is associated with a poor prognosis and a significant risk of
sudden cardiac death. Clinically, patients with LMNA related DCM should be specifically
identified for several reasons. First, cardiac defects eventually occur in almost all
patients carrying LMNA gene mutations manifesting with either isolated cardiac
phenotype or a variety of neuromuscular dystrophies (Lu, Muchir, Nagy, & Worman,
2011). Second, while mutation carriers of the disease are nearly 100% penetrant,
phenotype expressivity is variable among families with different LMNA mutations. Third,
conduction abnormalities, such as atrial fibrillation, atrioventricular block, asystole, or
potentially lethal ventricular arrhythmias typically precede cardiac dysfunction, and are
associated with a higher incidence of sudden death than those with other types of DCM
(Forleo et al., 2015; Goidescu, 2013).
Regardless of the familial background, the diagnosis should be suspected
(familial or sporadic form) when the patient presents with DCM and a conduction
deficiency; DCM and skeletal muscle anomaly (muscle weakness/wasting, tendon
contractures, increased creatine kinase level); or DCM preceded by supra-ventricular or
8

ventricular arrhythmia (Charron, Arbustini, & Bonne, 2012). When a diagnosis is
suspected based on the previous criteria, it should be validated through genetic testing
of LMNA. The confirmation should prompt a routine cardiac assessment, which should
include an ECG, echocardiogram, Holter-ECG, cardiac MRI with contrast, and exercise
testing. An evaluation of the skeletal muscles and serum creatine kinase or troponin
levels are also recommended. Cardiac examination and diagnostic genetic testing are
recommended for all first-degree relatives in the family (ages 10–12) (Charron et al.,
2010). Cardiac imaging is used to diagnose left ventricular enlargement, and twodimensional echocardiography, angiography, and/or MRI are used to assess impaired
systolic function(Hershberger & Morales, 1993).
At present, there is no specific optimal treatment for cardiac laminopathies.
Patients with LMNA cardiomyopathy are prescribed the same GDMT management
approaches as those with other cardiomyopathies or heart failure. History of competitive
physical activity was determined to be strong independent predictor of SCD (Pasotti et
al., 2008). Therefore, all LMNA mutation carriers, regardless of illness stage or
presence of cardiac problems, should avoid competitive sports. Chronic atrial fibrillation
is managed by the reestablishment of normal rhythm and rate, and anticoagulation.
Symptomatic supraventricular arrhythmias are normally treated with medication or
ablation. An ICD and necessary medication are used to treat symptomatic ventricular
dysrhythmia and resuscitated sudden cardiac death. Since heart block and
bradyarrhythmia are associated with a high chance of mortality caused by sudden
cardiac death in LMNA-related DCM, ICD application (instead of merely pacemaker
placement) has been advised (Hershberger & Morales, 1993). The placement of a
9

defibrillator can avert sudden death from arrhythmias, but progressive heart failure often
becomes unresponsive to medication, necessitating heart transplantation (Becane et
al., 2000; Ollila et al., 2017; X. Wang, Zabell, Koh, & Tang, 2017).
A growing population of pre-clinical CM-associated LMNA mutation carriers
represents a unique challenge. These carriers are frequently asymptomatic with only
early manifestation of the disease or are entirely pre-clinical on clinical evaluation.
Individuals in this group may never develop the condition that brought the proband to
attention. Alternatively, they may have a slower or milder progression. Unfortunately, we
have little to base an accurate prediction on in individual cases. Besides lifestyle
recommendations (generally avoidance of competitive athletics), clinical surveillance is
all that can be recommended and there are no gene-specific therapies to pre-empt
disease development. Medication used in affected and symptomatic family members is
not merited in pre-clinical individuals since they are not likely to impact the earliest
molecular and cellular processes triggered by the causative mutations. To achieve the
goal of Precision Medicine, early molecular pathways need better delineation to enable
biomarker predictors of disease progression and therapeutic targets for disease preemption.
Induced pluripotent stem cells (iPSC)
The original mouse induced pluripotent stem cells (iPSCs) were reprogrammed
from mouse fibroblasts by transfecting a set of 4 transcription factors (c-Myc, Oct3/4,
Sox2, and Klf4) retrovirally (Maherali et al., 2007; Okita, Ichisaka, & Yamanaka, 2007;
Wernig et al., 2007). Later, a similar method was used to generate human iPSCs
(Takahashi et al., 2007; Yu et al., 2007). Comparable to mouse iPSCs, human iPSCs
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resemble human embryonic stem cells and are capable of self-regeneration and
induction into numerous cell types, such as cardiomyocytes, cardiac fibroblasts,
endothelial cells, macrophages, and neurons. iPSCs reprogrammed from patientspecific somatic cells is ideal to study the underlying mechanisms of disease particular
to the patient in vitro. Recent progress in iPSC technology has enhanced its
applications to cardiac diseases (Yoshida & Yamanaka, 2017). iPSC-derived
cardiomyocytes model and reproduce the characteristics of genetic diseases and are
beneficial for tissue engineering, medication invention and toxicology screening.
Even though murine models are essential for function investigations on the whole
heart and intact animal, significant differences between rodent and human cardiac
physiologies do exist at the level of the genetic information, heart rate, systolic
contraction and diastolic filling time, ventricular action potential duration, repolarization
and plateau phase, myofilaments and ion channels (Milani-Nejad & Janssen, 2014).
Sources of human cardiomyocytes are inadequate due to the restricted availability of
primary cell lines and the difficulties of culturing them in vitro. iPSC technology
overcomes these limitations of mouse model or primary cell lines by taking advantage of
specific differentiation protocols to generate any cell type (Takahashi & Yamanaka,
2016). iPSC-based platform incorporates different LMNA mutations and models
“disease in a dish”, which holds promise to convert precision medicine into clinical
applications.
In terms of the pathogenesis of LMNA related DCM, a transgenic animal model
on the missense mutation of LMNA has provided some useful insights. Bonne’s group
introduced a homozygous H222P mutation in LMNA in a mouse model, which faithfully
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reproduced typical traits of human laminopathies including cardiac conduction
deficiencies, chamber enlargement, and massive cardiac fibrosis (Arimura et al., 2005).
Later, this tool was utilized as a platform for cardiac pathology investigation and drugtarget search. The extracellular signal-regulated kinase (ERK), a branch of the MAPK
signaling cascade, is found to be abnormally hyperactivated in human hearts with
LMNA related cardiomyopathy and from Lmna H222P/H222P mice. The inhibition of the
ERK pathway improved heart failure and survival rate in Lmna H222P/H222P mice, and
reestablished normal nuclear morphology (Muchir et al., 2007; Muchir, Reilly, et al.,
2012; Muchir, Shan, Bonne, Lehnart, & Worman, 2009). In addition, treatment of Lmna
H222P/H222P mice with a different branch of the MAPK cascade, p38α signaling
inhibitor ARRY-371797 ameliorated left ventricular dilatation and alleviated fractional
shortening in comparison to placebo-treated mice (Muchir, Wu, et al., 2012). However,
mouse models have either been complete knockout or homozygous point mutations to
obtain phenotypes. Moreover, the development of the MAPK-inhibition treatment was
based on a single mutation site in LMNA whereas a wide variety of mutation types and
sites within LMNA have been linked to heart disease.
Fortunately, recent advances in human pluripotent stem cells have enabled us to
model cardiac diseases and study the underlying mechanisms in vitro (i.e., hypertrophic
cardiomyopathy (Ojala et al., 2016), arrhythmogenic right ventricular cardiomyopathy
(Caspi et al., 2013) and long QT-syndrome (Lahti et al., 2012)). To date, a few studies
investigating LMNA-related cardiomyopathy using the iPSC-CM model have been
published. Siu et al. exhibited that MAPK inhibitors (U0126 and selumetinib) reduce
nuclear defects and apoptosis induced by electrical stimulation in iPSC-CMs carrying
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the LMNA R225X/WT mutation (Siu et al., 2012). In the following study, this group also
demonstrated that Ataluren (PTC124) treatment lessened nuclear blebbing and
electrical stress-induced apoptosis as well as the excitation-contraction delay of the
iPSC-CMs harboring LMNA R225X/WT, rather than LMNA Q354X/WT or LMNA
T518fs/WT (Y. K. Lee et al., 2017). The codon selective effect of PTC 124 emphasizes
the importance of studying different mutation types and sites within LMNA to achieve
the goals of personalized medicine for DCM treatment. Additional studies investigating
LMNA-related cardiomyopathy have been summarized in table 1.
Based on the published studies, distinct LMNA mutation seems to share some of
the common hallmarks of laminopathies. However, mutation-specific mechanisms may
be unrevealed. We postulate that there are early pre-clinical molecular and cellular
events that are mutation-specific and present opportunities for novel therapy
development. In this case, the medication used in affected and symptomatic family
members are not merited in pre-clinical individuals since they are not likely to impact the
earliest molecular and cellular processes triggered by the causative mutations. The
successful discovery of mutation-specific therapeutic targets will enhance the delivery of
Precision Medicine to complement cardiogenetic testing.
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Table 1. Present studies on LMNA related cardiomyopathy.
LMNA
mutation

Model

Clinical
Phenotypes

Molecular phenotypes

References

H222P

Point
mutation
mice

DCM,
muscular
dystrophy

Muchir et al., 2007,
Arimura et al.,2005,
Choi et al., 2013

D300N

Heart
specific
point
mutation
mice

DCM,
progeroid
syndrome

R160P
Q312H
R335W
Q353X

Postmortem
Human
hearts

DCM, VT,
VF, AF

R225X
Q354X
T518fs

Dermal
fibroblasts,
iPSC-CMs

DCM, AF, AV
block

R190W

iPSC-CMs

DCM

K291T

iPSC-CMs

DCM, AF, AV
block, LBBB

K117fs

iPSC-CMs

DCM, AF, AV
block, VT

Cardiac conduction
defeats, chamber
dilation and enhanced
fibrosis, MAPK and
mTOR activation
Myocardial fibrosis,
apoptosis, cardiac
dysfunction, and
premature death,
activation of the
E2F/DNA damage
response/TP53 pathway
Reorganization of
Lamin-Associated
Domains, increased
CpG methylation, DEGs
involved in cell
death/survival, cell
cycle, and metabolism.
Nuclear blebbing,
apoptosis, ERK1/2mediated susceptibility
to electrical stimulation
Sarcomeric
disorganization,
abnormal activation of
ERK1/2 signaling
Decreased Nav1.5
expression, decreased
sodium current density
and conduction velocity
Aberrant calcium
homeostasis, PDGF
signaling pathway
activation, increased
open chromatin

Chen et al., 2020

Cheedipudi et al.,
2019

Siu et al., 2012
Lee et al., 2017
Chatzifrangkeskou
et al., 2018
Salvarani et al.,
2019
Lee et al., 2019

AF atrial fibrillation or flutter; VT ventricular tachycardia, VF ventricular fibrillation, AV
block atrioventricular block, LBBB left bundle branch block
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For example, MAPK inhibitor, ARRY797 is currently under clinical trial phase 3.
The examination of MAPK pathway activation and investigational treatment of this drug
on patient-specific iPSC-derived cells in vitro will provide insight for customized clinical
recommendations tailored for a given patient. Overall, our project aims at unveiling the
mechanisms underlying different mutation types and sites within LMNA to achieve the
goals of Personalized Medicine for DCM treatment.
Hypothesis
Different patients had varying clinical presentations in terms of the contractile
dysfunction and electrical deficits. How different cell types carrying distinct LMNA
mutations take varying mechanistic routes leading to DCM remains unclear (Figure 3).
To fill this gap, we have recruited 7 patients with discrete point mutations on LMNA and
generated patient-specific iPSC lines using nonintegrating reprogramming methods. We
have differentiated these lines and healthy unrelated iPSCs into cardiomyocytes (iCMs)
and cardiac fibroblasts (iCFs) using chemically defined protocols to examine and
compare the cellular, molecular, genetic, and electrophysiological properties. A
successful conclusion of this study in iPSC model will offer a great prospect for
mechanism investigation and personalized therapy identification.
Working hypothesis 1: The physiological characteristics of iPSC-CMs bearing
different LMNA mutations are not uniform.
Aim 1：Determine phenotypic differences in iPSC-CMs bearing different LMNA
mutations.
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Figure 3. Central hypothesis: different mutation types and sites within the same
cardiomyopathy gene (in this case, LMNA) take different molecular routes, but converge
on common final phenotype of DCM.

LMNA variants have been characterized as benign, variants of unknown
significance, likely pathogenic, or pathogenic. It is unclear whether different LMNA
mutations can cause equivalent or various molecular phenotypes. To test this, I
reprogramed peripheral mononuclear cells (PBMCs) from 7 DCM patients carrying
different LMNA mutations, p.R216C & p.R399H, p.R216C, p. M1I, p.R335Q, p.R216C,
p.R541C, p.R377H (Figure 2A), into iPSCs and further differentiated them into
cardiomyocytes. Using our iPSC-CM system, I assessed and compared the LMNA gene
and protein expression, molecular pathways (MAPK pathway activation), lamina
architecture and sarcomeric structure, apoptosis, electrophysiological function and
transcriptome profile.
Working hypothesis 2: Cardiac fibroblasts contribute to LMNA Cardiomyopathy.
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Aim 2: Determine the role of cardiac fibroblasts in the progression of cardiac
laminopathies.
The cellular composition of the heart contains more non-myocytes than myocytes
(by cell number) (Gray, Toor, Castellan, Crisan, & Meloni, 2018; Tirziu, Giordano, &
Simons, 2010). Myocytes generally comprise about 25-40% of the cells. Endothelial
cells (EC) appear to be the most common non-myocyte cell type (estimates often above
60%). Cardiac fibroblast estimates have been more uncertain, ranging from 13-60%
(Bergmann et al., 2015; Pinto et al., 2016; P. Zhou & Pu, 2016). Cardiac resident nonmyocytes are now well acknowledged to participate and normal cardiac function and to
participate in pathological states (Brutsaert, 2003; Kamo, Akazawa, & Komuro, 2015).
LMNA is expressed widely expressed in most differentiated cells (Worman & Bonne,
2007; Worman, Lazaridis, & Georgatos, 1988). Intense cardiac fibrosis has been a
consistently observed feature in both human pathology and animal models of LMNAcardiomyopathy (Arimura et al., 2005; Chatzifrangkeskou et al., 2016; Raman et al.,
2007; Wu, Muchir, Shan, Bonne, & Worman, 2011). Studies on LMNA mutation
mechanisms in cardiomyopathy have largely focused on the cardiomyocyte, however,
with less consideration of the effect mutant LMNA exerts on non-myocyte resident
cardiac cells. To address this gap, we have adapted protocols to differentiate iPSCs into
cardiac fibroblasts.
LMNA has near-ubiquitous expression in differentiated cells (Lin & Worman,
1997). The concept of non-myocyte cardiac resident cells communicating with
myocytes in normal physiology and their contribution to cardiomyopathy is a rapidly
growing field (Colliva, Braga, Giacca, & Zacchigna, 2020; Gambardella, Trimarco,
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Iaccarino, & Sorriento, 2017; Hirsch, Nagai, & Thum, 2014; Hulsmans et al., 2017;
Narmoneva, Vukmirovic, Davis, Kamm, & Lee, 2004; Talman & Kivela, 2018). A
hallmark of LMNA-ACM is pronounced cardiac fibrosis (Arimura et al., 2005; S. N. Chen
et al., 2019; Raman et al., 2007). Molecular research on LMNA-ACM has largely
focused on cardiomyocyte effects with little known regarding how mutant LMNA affects
cardiac-resident non-myocytes.
Joseph Wu’s group has developed a robust chemically defined protocol to derive
cardiac fibroblasts from iPSCs (Zhang et al., 2019). In light of this protocol, I
differentiated iPSCs harboring different LMNA mutations into cardiac fibroblasts.
Baseline characterization of lamin A/C protein level, nuclear shape, MAPK pathway
activation and fibrosis level in iCFs and potential drug treatments were examined.
Furthermore, I determined the transcriptomic profile changes in mutated iCFs in
comparison to wildtype iCFs using RNA-sequencing. I conducted direct co-culture
studies of iCMs and iCFs to evaluate the role of cardiac fibroblasts in the complexity of
cardiac laminopathies.
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CHAPTER TWO
CELLULAR PHENOTYPIC ALTERATIONS IN LMNA-ICMS
Introduction
LMNA-associated diseases are pleiotropic. LMNA-cardiomyopathy exhibits
substantial phenotypic variation in age of onset and rate of progression. The
prominence of myopathy versus arrhythmia, the arrhythmia type (atrial, ventricular, or
conduction defects), their chronological sequence, and their combinations can greatly
vary from person to person. Our experience has been that members within a family will
more frequently present alike suggesting that it “breeds true”. While this could be
accounted for by different genetic backgrounds, the penetrance of LMNA-ACM within
each family is much higher than other Mendelian cardiac conditions such as long QT
syndrome, TTN-associated DCM (Herman et al., 2012; Jansweijer et al., 2017; Roberts
et al., 2015), or MYBPC3-associated HCM (Page et al., 2012; Williams et al., 2018).
Now that we are entering an era of Precision Medicine (and there is one
candidate drug (Pfizer ARRY-371797) in Phase-III trials that target MAPK pathway) it is
important to determine if this will be effective in all or selected carriers of LMNA
mutations. This question is appropriate since all the in vitro research leading to this
drug’s development was based on a transgenic mouse model with a single LMNA
mutation (Arimura et al., 2005; Muchir et al., 2009; Wu et al., 2011). Better insight into
the pathogenesis of DCM at the cellular level caused by different LMNA mutations will
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inform future therapeutic design. Therefore, I focused on comparing the MAPK pathway
along with LMNA expression and distribution, cellular structure, and electrophysiological
features in seven LMNA genotype-positive patients with different cardiac penetrance
and expressivity.
Because of the substantial interaction of LMNA with chromatin, dysregulated
gene expression has been proposed as a feasible mechanism to explain the phenotypic
variability of laminopathies (Hutchison, 2002). Accumulating evidence suggests that
LMNA mutation causes alterations in chromatin, gene activity as well as signaling
pathway, resulting in the progressive weakening of the cardiac muscle (Brayson &
Shanahan, 2017). Importantly, recent research found that lamina-associated domains
(LADs) are reorganized in LMNA-related DCM, which is linked with significant
alterations in CpG methylation and gene expression (Cheedipudi et al., 2019). By
performing RNA-sequencing from the entire heart of wildtype and LMNA D300N mice,
Marian’s group identified ~6,000 differentially expressed genes (DEGs). They further
denoted the E2F/DNA Damage Response/TP53 axis as a potential pathway involved in
LMNA related DCM (S. N. Chen et al., 2019). We have taken advantage of RNA-seq to
identify the overall transcriptome profiling and top disrupted genes caused by distinct
LMNA mutation.
Methods
Reprograming of PBMCs
We recruited seven patients of different families affected by DCM accompanied
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with arrhythmogenic conduction disorders. Recruitment was performed under the
approval of the Institutional Review Board of the University of South Florida (IRB:
Pro00033948). Participants have provided written informed consent. These
heterozygous mutations of LMNA were identified by arrhythmia and cardiomyopathy
comprehensive exon sequencing panels from genetic testing commercial laboratories
(Ambry Genetics, GeneDx, and Invitae). Table 2 summarizes clinical information in
detail.
Table 2. Clinical characteristics of subjects.
Subject
AA change
Control#1
ATCC 1026
Control#2
ATCC 1028
Control#3
ATCC 1029

Age Sex

Mutation
type

DCM
/CHF

AF

VA

CCD

SMD

Age
Onset

31

M

Wild type

-

-

-

-

-

NA

31

F

Wild type

-

-

-

-

-

NA

24

F

Wild type

-

-

-

-

-

NA

M1I

46

M

Altered
start codon

+

+

+

+

+

39y

R216C
/R399H

71

M

Missense

+

+

+

-

-

62y

R216C.m

45

M

Missense

-

-

-

-

-

R216C.f

34

F

Missense

-

-

-

-

-

R335Q

49

M

Missense

+

-

-

+

-

49y

R377H

54

F

Missense

+

+

-

-

-

40y

R541C

53

F

Missense

+

-

-

+

+

15y

Preclinical
Preclinical

Symbol (−) indicates absent; (+) present; DCM indicates dilated cardiomyopathy; CHF
congestive heart failure; AF atrial fibrillation or flutter; VA ventricular arrhythmia; CCD
cardiac conduction disease (AV block or bundle branch block); SMD skeletal muscle
disease; NA not applicable or not available; AA amino acid; LGE late gadolinium
enhancement on cardiac magnetic resonance imaging.
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Reprogramming procedures can be found in previous publications (Angulo et al.,
2021; Argenziano et al., 2021; J. Yang, Argenziano, et al., 2021; J. Yang, Burgos
Angulo, et al., 2021; J. Yang, Samal, Burgos Angulo, Bertalovitz, & McDonald, 2021).
Standard, aseptic technique was applied for Vacutainer venipuncture and blood draw
using 2 CPT tubes per patient (~6ml blood each). The blood sample was centrifuged at
room temperature (18-25ºC) at 1500 to 1800 RCF for 20-30 minutes. Mononuclear cells
and platelets were found in a white layer just beneath the plasma level. PBMCs were
collected and washed with phosphate buffered saline (PBS) by centrifuge for 15
minutes at 300 RCF. Fresh PBMCs can be cultured directly or frozen for future use.
PBMCs were cultured in a complete PBMC medium composing of StemPro™-34 SFM
Blood Media (Thermo Fisher) with cytokines (100 ng/mL SCF (Peprotech), 100 ng/mL
FLT3 (Thermo Fisher), 20 ng/mL IL-3 (Peprotech) and 20 ng/mL IL-6 (Peprotech)) for 47 days. Cytokines were aliquoted and added freshly. Non-integration Sendai virus
vectors (Thermo Fisher) carrying human Yamanaka factors OCT3/4, SOX2, KLF4, and
c-MYC were transduced in PBMCs as per the manufacturer's protocol. Briefly, PBMCs
were plated at 5 × 105 cells/ml in a 24-well plate in the complete PBMC medium for
transduction. Cells were transduced using the CytoTune® 2.0 Sendai reprogramming
vectors at an MOI of KOS: c-Myc: Klf4 at 5:5:3 using a live cell count of 5 × 105 cells to
1 mL of PBMC medium. Cells containing virus were transferred to sterile, round-bottom
culture tubes sealed with Parafilm® laboratory film and centrifuged at 2250 rpm for 90
minutes at room temperature. After centrifugation, the cells in the medium containing
the virus were moved to a 12-well plate and supplemented with an additional 1 mL of
complete PBMC medium to each well for overnight incubation at 37°C in a humidified
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atmosphere of 5% CO2. On the second day, cells were centrifuged at 200 × g for 10
minutes and resuspended in 0.5 mL of complete PBMC medium per well of a 24-well
plate. On the third day, 10,000 and 50,000 live PBMCs were replated per well of a 6well plate coated with Matrigel (Corning) in 2 mL of complete StemPro®-34 medium
without the cytokines. Every other day from day 4-6, 1 mL (half) of the spent medium
was replaced with 1 mL of fresh complete StemPro®-34 medium without cytokines and
without disturbing cells. On day 7, 1 mL (half) of StemPro®-34 medium was removed
from the cells and replaced with 1 mL of iPSC medium-mTeSR plus medium
(STEMCELL Technologies), to start the adaptation of the cells to the new culture
medium. On day 8, the full volume was changed to mTeSR plus medium. The spent
medium was replaced every two days thereafter.
Colonies appeared near day 12 and continued to grow to an appropriate size for
transfer. The culture dish was examined at 10X magnification under an inverted
microscope. The colony to be picked was marked on the bottom of the culture dish.
Using a 200 μL pipette, the scraped pieces of the colony were transferred to a freshly
prepared 6-well Matrigel-coated culture plate containing mTeSR plus media with ROCK
inhibitor Y27632 (Sigma-Aldrich) at 10 μM. At least 10 distinct colonies were picked by
the end of each reprogramming experiment and were expanded in separate wells of 6well culture plates. The colonies to allowed to attach to the culture plate for 48 hours
before replacing the spent medium with fresh complete mTeSR plus Medium. After that,
change the medium every other day. Colonies were manually picked successively until
highly purified iPSCs were obtained and stored as frozen stocks.
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iPSC culture and iCM differentiation
Cells were cultured in a humidified atmosphere (95% air, 5%CO2) at 37° C.
Wildtype iPSC lines without LMNA mutation were purchased from ATCC company.
mTeSR plus medium (STEMCELL Technologies) was used to cultivate iPSCs on 6/12well plates coated with Matrigel (Corning). Cells were detached with 0.5 mM EDTA
solution (Invitrogen) in DPBS. Cell passage was performed every three to five days
using ROCK inhibitor Y27632 (Sigma-Aldrich) at 10 μM in mTeSR plus media.
Mycoplasma tests were regularly carried out. iPSCs underwent karyotyping of Gbanded metaphase chromosomes after 20 passages. iPSCs varying from P20 to P30
were used for differentiation.
All iPSC lines were induced towards cardiomyocytes with STEMdiff™
Cardiomyocyte Differentiation Kit (STEMCELL Technologies), according to the
company's protocol. Human iPSC colonies were cultured in a 12-well format in mTeSR
plus media for 2-4 days until >90% confluency. To induce the cells into cardiomyocytes,
the mTeSR plus medium is substituted with Medium A containing Matrigel (1:100). On
day 2, the medium is replaced completely with Medium B. Complete medium
replacements with fresh Medium C are conducted on days 4 and 6. To enhance further
differentiation into cardiomyocytes, the medium is converted to STEMdiff™
Cardiomyocyte Maintenance Medium on day 8, with the full medium replacement on
days 10, 12, and 14. On day 8, little beating regions of cardiomyocytes can be visible,
developing to a broad field of beating cardiomyocytes that can be collected at day 15.
Cardiomyocytes were then cultured in RPMI 1640 medium (Thermo Fisher) with
B27 (Thermo Fisher) supplement until day 30. Given that in differentiating iCMs, ~10%
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of cells become fibroblasts. To eliminate this contamination, we regularly employ a
glucose starvation interval. After day 30, cardiomyocytes were purified and enriched for
5 days with glucose deprivation (RPMI + B27 without glucose) as previously described
(Sharma et al., 2015). Cardiomyocyte dissociation media (STEMCELL Technologies)
was used to dissociate cardiomyocytes for downstream applications and analyses.
Sanger sequencing
The iPSC lysate was homogenized via the QiaShredder (Qiagen). Total RNA
was extracted using RNeasy Mini Kit (Qiagen) and converted to cDNA with SuperScript
VILO master mix or SuperScript IV Reverse Transcriptase (Thermo Fisher).
Alternatively, genomic DNA was isolated by QIAamp® DNA Mini Kit (Qiagen). cDNA or
genomic DNA were amplified with DreamTaq polymerase (Thermo Fisher) or Q5 Hot
Start High-Fidelity 2X Master Mix (New England Biolabs). Monarch PCR & DNA
cleanup kit (New England Biolabs) was used to purify PCR products, which were sent to
Genewiz or Eurofins Genomics laboratories for Sanger sequencing.
Real-Time (RT) PCR
1ng cDNA was amplified using Applied Biosystems TaqMan Fast Advanced
Master Mix (Thermo Fisher) in a 10μl reaction on the Step One Plus system (Applied
Biosystems). GAPDH was used as reference gene. Mutated lines were compared to
three biological control cell lines in triplicate. The ΔΔCt method, i.e., cycle thresholds
(Ct), was used to calculate relative gene expression normalized to GAPDH expression
as housekeeping genes (HKG). Fold changes in target gene expression were then
normalized to HKG via the published comparative 2 − ΔΔCt method using the formula:
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ΔΔCt = (Ct target-Ct HKG) treated - (Ct target-Ct HKG) control (Livak & Schmittgen, 2001).
Statistical analysis was performed on GraphPad Prism. The following TaqMan Assay
probes (Thermo Fisher) were used: GAPDH (Hs02786624_g1), GJA1
(Hs00748445_s1), SCN5A (Hs00165693_m1), KCNH2 (Hs04234270_g1), KCNQ1
(Hs00165003_m1), ATP2A2 (Hs00544877_m1), CASQ2 (Hs00154286_m1).
Immunofluorescence
Cells were plated on a 4-well chamber slide (NEST Scientific) and fixed with 4%
paraformaldehyde (w/v; Sigma-Aldrich) for 10 min. Cells were permeabilized with 0.2%
Triton X-100 (Sigma-Aldrich) for 10 minutes. Cells were then blocked for 30 minutes in
PBST (PBS + 0.1% Tween 20) with 1% BSA (Sigma-Aldrich) and 22.52 mg/ml glycine
(Fisher Scientific), then incubated with the primary antibody in 1% BSA overnight at 4°C
and secondary antibody (Thermo Fisher) for 1 hour in the dark at room temperature.
The antibodies used were summarized in table 3. VECTASHIELD HardSet Antifade
Mounting Medium with DAPI (VECTOR Laboratories) was employed to mount cells.
Fluorescence imaging was obtained using BZ-X800 Microscope (Keyence) and
FluoView FV1000 Confocal Microscope (Olympus). Nuclear circularity was calculated
using ImageJ software (circularity =4π*area/perimeter^2). TT power analyses with the
TTorg plugin in ImageJ were utilized to analyze sarcomere organization (Pasqualin,
Gannier, Malecot, Bredeloux, & Maupoil, 2015). iPSC pluripotency was further
confirmed using Stemgent® Alkaline Phosphatase Staining Kit II (REPROCELL).
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Table 3. Antibodies used in this study.

Mouse anti-SSEA4
Rabbit anti-OCT4
Rabbit anti-SOX2
Mouse anti-TRA-1-60
Mouse anti-cTnT
Rabbit anti-vimentin
Mouse anti-lamin A/C
Mouse anti-α-actinin
Rabbit anti-connexin 43

Use

Immunofluorescence

Primary

Antibody

IRDye® 800CW Donkey
anti-Mouse IgG
IRDye® 800CW Donkey
anti-Rabbit IgG
IRDye® 680RD Donkey
anti-Mouse IgG
IRDye® 680RD Donkey
anti-Rabbit IgG

Immunofluorescence

Rabbit anti-PAX6
Mouse anti-Nestin
Goat anti-brachyury
Mouse anti-α-SMA
Rabbit anti-SOX17
Mouse anti-AFP
Donkey Anti-Mouse IgG
(H+L) Antibody, Alexa Fluor
488 rabbit
Donkey anti-Mouse IgG
(H+L) Antibody, Alexa Fluor
594
Donkey anti-Rabbit IgG
(H+L) Antibody, Alexa Fluor
488
Donkey anti-Rabbit IgG
(H+L) Antibody, Alexa Fluor
594
Donkey anti-goat IgG (H+L)
Antibody, Alexa Fluor 647

Immunoblot

Secondary

Rabbit anti-cleaved caspase
3
Mouse anti-lamin A/C

Immunoblot

Rabbit anti-pERK
Mouse anti-total ERK

Dilution

Company Cat #

1:200
1:200
1:200
1:200
1:200
1:200
1:100
1:800
1:200
1:1000
1:1000
1:1000

Thermo Fisher Scientific Cat# 41-4000
Thermo Fisher Scientific Cat# PA1-16943
Thermo Fisher Scientific Cat# PA1-094
Thermo Fisher Scientific Cat# 14-8863-82
Santa Cruz Biotechnology Cat# sc-20025
Abcam Cat# ab 45939
Thermo Fisher Scientific Cat# MA3-1000
Sigma-Aldrich Cat# A7811
Cell Signaling Technology Cat# 3512s

1:1000
1:1000

Cell Signaling Technology Cat# 9101s
Santa Cruz Biotechnology Cat# sc514302
Cell Signaling Technology Cat# 9661s

1:200
1:200
1:50
1:200
1:200
1:200
1:500

Santa Cruz Biotechnology Cat# sc376248
Thermo Fisher Scientific Cat# 42-6600
Thermo Fisher Scientific Cat# MA1-110
R&D system AF2085
Abcam ab7817
Proteintech Cat# 24903-1-AP
Thermo Fisher Scientific Cat# MA1-19178
Thermo Fisher Scientific Cat# A-21202

1:500

Thermo Fisher Scientific Cat# A-21203

1:500

Thermo Fisher Scientific Cat# A-21206

1:500

Thermo Fisher Scientific Cat# A-21207

1:500

Thermo Fisher Scientific Cat# A-21447

1:10000

LI-COR Cat# 925-32212

1:10000

LI-COR Cat# 925-32213

1:10000

LI-COR Cat# 925-68072

1:10000

LI-COR Cat# 925-68073
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Immunoblotting
Cell samples were collected with RIPA buffer (Thermo Fisher) supplemented with
protease and phosphatase inhibitors (Thermo Fisher) and sonicated in short bursts and
centrifuged at 15,000 rpm for 15 min. The protein concentration of the supernatant was
measured using Bradford assay (Thermo Fisher). An equal amount of total protein was
loaded on a 4–15% SurePAGE gradient gel (GenScript) or a 4–15% Mini-PROTEAN®
TGX™ Precast Protein Gel (Bio-Rad). After separation, the proteins were electroblotted
onto nitrocellulose membrane using Trans-Blot Turbo Transfer System (Bio-Rad). Total
protein normalization was completed by REVERT stain (Li-COR) by incubation in
Revert 700 Total Protein Stain, and then rinsing twice with Revert 700 Wash Solution.
PBS Odyssey Blocking Buffer (Li-COR) was used to block membranes for 1 h at room
temperature, which was further incubated with primary antibodies overnight at 4°C and
secondary antibodies for 1 h at room temperature. The primary and secondary
antibodies used were listed in table 3. Images were acquired using an Odyssey FC or
CLX imaging system.
Microelectrode array (MEA)
The Maestro Edge multiwell MEA platform (Axion Biosystems) is equipped with a
smart environmental chamber and has a built-in gas delivery port to enable a finely
controlled temperature and CO2 condition while rejecting electrical noise and
mechanical vibrations throughout the measurements. Each well of 24-well MEA plates
was coated with 5 μl of fibronectin (F1141, Sigma-Aldrich) at 50 μg/ml onto electrode
region and incubated for 1 hour before cell seeding. After removal of fibronectin, iCMs
were plated at 100,000 viable cells per well of MEA plates (Axion Biosystems). Each
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well was then filled with a culture medium at a volume of 0.5 mL/well. For coculture, the
mixture of 90,000 iCMs and 10,000 iCFs was seeded per 24-well on MEA. The cells
were then incubated for 2 weeks before recording with Maestro MEA system.
Contractility, extracellular field potential and propagation were recorded for 10 min from
spontaneously beating cells at 37°C/5% CO2 with Axis Navigator software (Axion
Biosystems). Corrected field potential duration (FPDc) was calculated based on
Fridericia’s formula: FPDc = FPD/Beat period^1/3 (Asakura et al., 2015). All mutated
lines were compared relative to the average of three biological controls. Independent
experiments were repeated 3 times in at least 3 wells/ cell line.
Calcium imaging
Calcium imaging was performed on BZ-X800 Microscope system (Keyence),
which allows for the mounting of temperature/CO2 regulated chamber for
cardiomyocyte imaging. iCM monolayer was detached, separated into single
cardiomyocyte, and replated on Matrigel-coated glass-bottom 12-well plates. The
spontaneous beating was recovered 2-7 days later. iCMs were stained with fluorescent
calcium dye Fluo-4 AM (F14217, Thermo Fisher) at 5 μm in calcium-free Tyrode’s
solution (NaCl 134 mm, KCl 5.4 mm, MgCl2 2 mm, HEPES 10 mm, Glucose 10 mm) for
15–20 min, washed with Tyrode’s solution for 15 min at 37° C, and imaged in Tyrode’s
solution containing 2 mm Ca2+. Calcium transient was recorded for 1–2 min. ImageJ
software was used to measure the mean intensity of the fluorescence signal. The Ca2+
levels were described as values of ΔF/F0 with subtraction of background noise.
Bradycardia was identified as a beating rate 2 standard deviations below the average of
the controls.
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RNA-sequencing
Sample collection and preparation
Cells were homogenized via the QiaShredder (Qiagen), and total cellular RNA
was isolated using the Qiagen RNA isolation kit. RNA concentration was quantified
using the Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments). RNA
samples were sent to Novogene Bioinformatics Technology for Illumina sequencing and
initial bioinformatic analysis. The specific steps are described below.
RNA quantification and qualification
RNA degradation and contamination were evaluated on 1% agarose gels. The
NanoPhotometer® spectrophotometer was used to assess the purity of the RNA
(IMPLEN, CA, USA). The Bioanalyzer 2100 system's RNA Nano 6000 Assay Kit was
used to examine RNA integrity and quantification (Agilent Technologies, CA, USA).
Library preparation
1 g total RNA of each sample was utilized to generate sequencing libraries using
the NEBNext® UltraTM RNA Library Prep Kit for Illumina® (NEB, USA). Unique index
codes were added to assign sequences per sample. mRNA was enriched from total
RNA by poly-T oligo-attached magnetic beads. In the NEBNext First Strand Synthesis
Reaction Buffer (5X), fragmentation was carried out utilizing divalent cations at a high
temperature. Double-stranded cDNA synthesis was accomplished by using M-MuLV
Reverse Transcriptase, random hexamer primers, Polymerase I and RNase H. End
repair were accomplished by exonuclease/polymerase, followed by poly-A adenylation
at 3' ends of DNA fragments and adaptor ligation of NEBNext adaptor with hairpin loop
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structure. AMPure XP technology selected cDNA fragments with a preferred length of
150–200 bp (Beckman Coulter, Beverly, USA). Samples were then incubated with 3 ul
USER Enzyme (NEB, USA) for 15 minutes at 37 °C, followed by 5 minutes at 95 °C.
Next, PCR was carried out using Phusion High-Fidelity DNA Polymerase, Universal
PCR primers, and Index (X) Primer. Lastly, PCR products were purified using the
AMPure XP system and the library quality was determined using the Agilent Bioanalyzer
2100 system.
Clustering and sequencing
The index-coded samples were clustered via the PE Cluster Kit cBot-HS
(Illumina) on a cBot Cluster Generation System as per the manufacturer's instructions.
The library was prepared on an Illumina platform and paired-end reads were obtained
after cluster formation.
Data Analysis
Quality control
Fastp was employed to process the raw data (raw readings) in the FASTQ
format. Clean data/reads were generated by eliminating adaptor and poly-N sequences
from raw data, along with low-quality reads. Meanwhile, the clean data's Q20, Q30, and
GC content were determined. All the subsequent analyses were constructed on clean,
high-quality data.
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Mapping to reference genome
Reference genome and gene model annotation files were downloaded from
genome website browser (NCBI/UCSC/Ensembl). The Spliced Transcripts Alignment to
a Reference (STAR) software was used to align paired-end clean reads to the reference
genome. STAR is based on an RNA-seq alignment algorithm that uses a previously
uncharacterized sequential maximum mappable seed search in uncompressed suffix
arrays, followed by seed clustering and stitching. STAR outperforms other RNA-seq
aligners in both actual and simulated data in terms of accuracy and sensitivity.
Quantification
The read counts mapped for each gene were counted using FeatureCounts.
Then, depending on the length of the gene and the number of reads mapped to it, the
RPKM (Reads Per Kilobase of Exon Model per Million Mapping Reads) of each gene
was computed. RPKM is the most widely used approach for predicting gene expression
levels since it takes into account the impact of sequencing depth and gene length
simultaneously (Mortazavi, Williams, McCue, Schaeffer, & Wold, 2008).
Differential expression analysis
The DESeq2 R software was used to compare the expression levels of two
conditions/groups (three biological replicates per condition). DESeq2 uses a model
based on the negative binomial distribution to determine differential expression in digital
gene expression data. The False Discovery Rate (FDR) was controlled using Benjamini
and Hochberg's technique. Differentially expressed genes were defined as those
discovered by DESeq2 with an adjusted p-value 0.05. The read counts were corrected
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by Trimmed Mean of M values (TMM) through one scaling normalization factor before
differential gene expression analysis for each sequenced library. In the absence of
biological duplicates, the edgeR R package was used to perform differential expression
analysis of two conditions. The Benjamini and Hochberg methods were used to adjust
the P values. The threshold for significantly differential expression was established at
corrected p-value < 0.05 and |log2 (Fold Change) | > 1.
Enrichment analysis
Incorporating biological knowledge offered by biological ontologies is a typical
approach to searching for shared functions among genes. In a directed acyclic graph
structure, Gene Ontology (GO) annotates genes to in biological process (BP), cellular
component (CC), and molecular function (MF), Kyoto Encyclopedia of Genes and
Genomes (KEGG) annotates genes to pathways, and Reactome annotates genes to
pathways and reactions in human biology. The cluster profile R package was used to
perform GO, KEGG and Reactome enrichment analysis of differentially expressed
genes, with a corrected P value less than 0.05 considered as significant.
Statistics
Independent experiments were repeated at least 2 times. Data are shown as
mean ± SEM. Statistical analysis among 2 groups was performed by unpaired t-test.
Multiple comparison correction analysis was performed using one-way ANOVA followed
by Tukey’s post-hoc test. P < 0.05 was considered statistically significant.
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Results
Establishment of iCM model
In 2018 we established the USF-Cardiogenetics Clinic. The clinic is supported by
the Division of Cardiology (Medicine), Genetics (Pediatrics), and the Genetic
Counseling Graduate Program (College of Public Health). The focus is Mendelian
cardiac disorders (hereditary arrhythmias and cardiomyopathies) in both adults and
children. The Clinic has a referral base across the state of Florida. Patients are invited
to participate in the Modeling Cardiogenetic Conditions in Cell Culture program if they
are found to have a pathogenic mutation associated with their condition (University of
South Florida IRB: Pro00033948). This protocol involves the collection of blood to
isolate PBMCs that are banked for reprogramming into iPSCs. De-identified clinical
phenotyping data (including age, gender, ethnicity, medical history, cardiac studies,
genetic testing results, and pedigree) are collected and linked to the de-identified
samples.
In this project, seven patients carrying heterozygous LMNA missense point
mutation M1I, R216C/R399H, R216C-male (R216C.m), R216C-female (R216C.f),
R335Q, R377H and R541C were enrolled from Cardiogenetic. LMNA subject
R216C/R399H is compound heterozygous in trans and the father of R216C.m.
R216C.m and R216C.f are recruited from two unrelated different families. We obtained
blood samples from these patients and isolated PBMCs to reprogram them into iPSCs
via nonintegrative Sendai virus that delivered Yamanaka factors. Sanger sequencing
validated the mutated genotyping in LMNA (Figure 4A). Three biological iPSC lines
absent of LMNA mutation were used as controls. The establishment of R541C iPSC line
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has been previously described in detail (J. Yang, Burgos Angulo, et al., 2021). Similarly,
pluripotency markers including SOX2, TRA-1-60, SSEA4, OCT4 and alkaline
phosphatase were validated in the seven cell lines (Figure 4B). Prior to differentiation
and analysis, each iPSC line is subjected to G-banding karyotype analysis to verify the
absence of major chromosomal rearrangements.
We compared several published and commercial protocols for the differentiation
of iPSCs into iCMs including a chemically defined small molecule differentiation protocol
by Paul W Burridge et al. (Burridge, Holmstrom, & Wu, 2015; Burridge et al., 2014), an
alternative chemical-defined and albumin-free culture system (S12 medium) for cardiac
differentiation (Pei et al., 2017), STEMdiff™ Cardiomyocyte Differentiation Kit (StemCell
Technologies) and PSC Cardiomyocyte Differentiation Kit (Thermo Fisher). While each
was successful, the one that exhibited the most efficiency and consistency in our lab
was the commercial product from StemCell Technologies (STEMdiff™ Cardiomyocyte
Differentiation Kit). As shown in Figure 4C, we reliably produce iCMs in 8-12 days after
initiation of the procedure from control and Cardiogenetic research subject cell lines.
Immunostaining demonstrated the cardiac-specific marker troponin T (Figure 4D).
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Figure 4. Differentiation and characterization of induced pluripotent stem cell (iPSC)derived cardiomyocytes (iCMs). (A) Sanger sequencing validates the presence of the
individual mutation. (B) Representative staining of iPSCs expressing pluripotency
markers SOX2 (green) and TRA-1-60 (red), SSEA4 (green), OCT4 (red), and alkaline
phosphatase. Nuclei were stained with DAPI (blue). (C) Schematic of cardiac
differentiation using STEMdiff™ Cardiomyocyte Differentiation kit. (D) Immunostaining
of cardiac troponin T positive cardiomyocytes. Scale bar, 100 μm.
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Different LMNA-iCMs demonstrate varying amounts of lamin A/C, ERK
hyperactivation, and cleaved caspase-3
RT-PCR showed relative upregulation of LMNA mRNA in differentiated cells
(iCMs and iCFs) in comparison to the original iPSCs (Figure 5A). To evaluate how
different mutations affected LMNA protein abundance, we performed immunoblot
analysis of lamin A/C protein in iCMs (Figure 5B). We observed variable expression
levels of lamin A/C among iCMs from different donor iPSCs, supporting our hypothesis
that different mutations lead to disease by unique mechanisms.
Whether different missense mutations of LMNA cause hyperactivation of ERK
pathway and affect cardiac function is still unknown. To answer this question, we
examined MAPK signaling as reflected by ERK activation (measured by
phosphoERK/total ERK) in iCMs from different LMNA subjects. We observed that in
iCMs 35-days after differentiation, four lines had statistically elevated ERK activation
compared to control lines (Figure 5C).
In addition, cell death and apoptosis have also been demonstrated in LMNA-CM
(Siu et al., 2012, Shah et al., 2019). Figure 5D shows that cleaved caspase-3, a critical
executioner of the apoptotic pathway, is variably increased among the LMNA-iCMs we
have examined to date. These results each suggest a variety of mechanisms that could
be mutation specific.
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Figure 5. Variable levels of lamin A/C, extracellular signal-regulated kinase (ERK)
pathway hyperactivation, and cleaved caspase-3 in different LMNA-iCMs. (A) RT-PCR
showing relative LMNA mRNA level in iPSC, iCM and iCF from the same control cell
line. (B) Immunoblot showing lamin A/C and total protein expression in seven mutated
and three control iCMs. The lower blot illustrates total protein loading. Histogram below
blots demonstrates normalized lamin A/C expression quantification in three control iCMs
and seven LMNA subjects. (C) Immunoblot of phosphorylated ERK1/2 (pERK1/2 in top
blot) and total ERK1/2 (in middle blot) from iCMs. Histogram below blots shows
pERK1/2 activity in iCMs calculated as the ratio of pERK1/2 over total ERK1/2. (D)
Immunoblot for cleaved caspase-3 from iCMs (top blot). Histogram below blots shows
quantitation normalized cleaved caspase-3 in iCMs. Combined results from three
controls are shown. Results are expressed as means ± S.E.M. of three independent
experiments. *p < 0.05.

Normal nuclear morphology and sarcomere disorganization in LMNA-iCMs
Previous data on mature adult CMs and iCMs from patients carrying LMNA
mutations have reported nuclear dysmorphism (Y. K. Lee et al., 2017; Siu et al., 2012).
When we examined nuclear morphology of lamin A/C we observed no discernable
abnormality or differences in circularity in LMNA-subject iCMs matured for 35–40 days
(Figure 6A,6C). However, there was apparent evidence (and in some lines, marked) of
sarcomere disarray, as indicated by a fragmented and dotted staining pattern of the
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cardiac marker, α-actinin. The percentage of cells with severe sarcomeric abnormalities
was substantially higher in DCM-iCMs than in controls (Figure 6B,6D).

Figure 6. Characterization of lamin A/C nuclear morphology and sarcomere structure in
iCMs. (A) Representative immunofluorescence micrographs of lamin A/C (green) and
lamin B1 (red) in iCMs. Nuclei were stained with DAPI (blue). Scale bar, 10 μm. (B) αactinin (red) staining of cardiomyocytes revealed sarcomeric abnormalities (fragmented
and punctuated staining) in LMNA mutant-iCMs. Nuclei were stained with DAPI (blue).
Scale bar, 5 μm. Insets illustrate magnified areas in dotted white boxes (scale bar, 5
μm). Line scans show striation patterns for sarcomeric α-actinin distributions (y-axis, the
fluorescence intensity in arbitrary units; x-axis, distance in μm).
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Figure 6 (continued). (C) Scoring of iCMs nuclear morphology assessed by circularity
(n > 100). (D) Immunostaining quantification shows the percentages of the disorganized
sarcomere in mutant iCMs compared to controls (n > 20). Combined results from three
controls are shown. Data are expressed as means ± S.E.M. of two independent
experiments. *p < 0.05.

Abnormal calcium transient in LMNA mutated cardiomyocytes derived from
iPSCs
We examined the Ca2+-transient properties of the iCMs by using Fluo-4, a
fluorescent calcium indicator. In addition to some normal Ca2+ transients, LMNA-iCMs
showed a wide range of calcium mishandling transients including alternans, slow beat
rate, early afterdepolarization, oscillations, and fibrillations (Figure 7A). LMNA mutants
presented with a notably greater occurrence of these abnormal intracellular calcium
signaling (Figure 7B), which may render arrhythmogenic disturbances to LMNA-DCM
patients clinically.
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Figure 7. Analysis of calcium handling in all iCMs. (A) Representative calcium transient
from LMNA mutant- and control-iCMs showing (from left to right) normal, alternans,
slow, early afterdepolarizations (EAD), oscillations, and fibrillations. (B) Quantification of
the frequency of various proarrhythmic events in all iCM lines (n > 40). Combined
results from Control #1, Control #2 and Control #3 are shown as control. Data are
expressed as means ± S.E.M. of three independent experiments. *p < 0.05.

The mutations in LMNA cause electrophysiological perturbations in iCMs
To assess the electrophysiological activity of spontaneously beating monolayers
of cells carrying diverse LMNA mutation, we use a multi-electrode array system with 12well plates and 16 electrodes/well. This system has the capability of measuring field
potentials, impedance measurements of mechanical activity, action potentials. Figure
8A shows an example of field potential measurements obtained from iCMs. Mutated
iCMs demonstrated increased beat period (diminished beating rates) and corrected
FPD and excitation-contraction and reduced conduction velocity compared to wildtypes
(Figure 8B-8E).
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Figure 8. Analysis of electrophysiological characteristics on micro electrode array in all
iPSC-CMs. (A) Representative extracellular field potential recording of the iPSC-CM
monolayers on an MEA showing beat period, depolarization spike, repolarization bump
(T-wave) and field potential duration. Histograms show the distribution of recorded (B)
Beat period, (C) Field potential duration corrected (FPDc), (D) Conduction velocity, (E)
Excitation-contraction delay (E-C delay); n = 3 wells per group. Combined results from
Control #1, Control #2 and Control #3 are shown as control. Data are expressed as
means ± S.E.M. of three independent experiments. *p < 0.05.

Altered ion channel expression in iCMs with different LMNA mutations
We investigated the mRNA levels of several ion channels that are important in
electrophysiology and calcium dynamics of cardiac myocytes. Different LMNA-iCMs
displayed a varying reduction of Sodium Voltage-Gated Channel Alpha Subunit 5
(SCN5A), Potassium Voltage-Gated Channel Subfamily H Member 2 (KCNH2) and
Potassium Voltage-Gated Channel Subfamily Q Member 1 (KCNQ1) (Figures 9A-C).
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Remarkably, LMNA-M1I and -R377H iCMs demonstrated an increased mRNA of
sarcoplasmic/endoplasmic reticulum calcium-ATPase 2 (ATP2A2), phospholamban
(PLN) and calsequestrin 2 (CASQ2) by qPCR. R216C.f also showed increased ATP2A2
and PLN (Figures 9D–F). GJA1, the encoding gene of connexin 43 (Cx43), is a critical
constituent of cardiac gap junctions. qPCR showed significantly reduced mRNA level of
Gap Junction Protein Alpha 1 (GJA1) in R335Q- and R377H- iCMs (Figure 9G), with a
relatively lower trend in the expression of Cx43 protein by immunoblot in comparison to
the controls (Figure 9H, 9I).

Figure 9. Analysis of ion channel levels in iCMs. RT-PCR data showing mRNA
transcripts in iCMs of (A) SCN5A, (B) KCNH2, (C) KCNQ1, (D) ATP2A2, (E) PLN, (F)
CASQ2, (G) GJA1. (H) Immunoblot showing connexin 43 (Cx43) expression in seven
mutated and three control iCMs. (I) Densitometry of Cx43 levels in all iCM lines
normalized to total protein and relative to three combined controls. Combined results
from Control #1, Control #2 and Control #3 are shown as control. Data are expressed
as means ± S.E.M. of three independent experiments. *p < 0.05.
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Investigation of potential therapeutic interventions in iCFs
Muchir et al. validated an abnormal increase in both MAPK and mTOR activity in
heart tissue from Lmna H222P mice (Muchir et al., 2007), which may offer an attractive
therapeutic opportunity for LMNA-ACM. Daily injection with MEK (MAPK–extracellular
signal-regulated kinase) 1/2 inhibitor (selumetinib) by this group to Lmna H222P mice
led to left ventricular (LV) end-systolic dilatation, increased ejection fraction, and
decreased cardiac fibrosis (Wu, Iwata, Homma, Worman, & Muchir, 2014). Besides the
hyperactivated ERK1/2 signaling, activities of the other stress response MAPKs, JNK
and p38, were also abnormally increased at an early stage of disease in Lmna H222P
mice hearts. Inhibiting JNK (SP600125) or p38 (ARRY797) exerted favorable effects on
LV dysfunction in the mice (Choi, Muchir, et al., 2012; Muchir, Wu, et al., 2012; Wu et
al., 2014; Wu et al., 2011). KLF2 inducer lovastatin improved endothelial dysfunction in
LMNA iPSC-ECs, the functionality of LMNA iCMs when cocultured with LMNA iPSCECs, and in patients with LMNA-related DCM (Sayed et al., 2020). However, the
rescuing effects of lovastatin in iCFs have not been studied. Figure 10 summaries the
potential interventional targets and readouts in our iCFs (Y. K. Lee et al., 2016).
We therefore examined the response to treatments with agents targeting 5
molecular pathways in R377H-iCFs. We administered 5 regents targeting MEK1/2ERK1/2 (selumetinib, 1 µM), p38 (ARRY-797, 1 µM), JNK (SP600125, 1 µM),
AKT/mTOR (everolimus, 1 µM), and KLF2 (lovastatin 0.1 µM) to LMNA-R377H-iCFs for
3 weeks. The relative expression of pERK/ERK, type I collagen, type III collagen,
fibronectin, and LMNA proteins was quantified and compared to wildtype iCF.
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Figure 10. Comparison of pharmacological treatment on targeted pathways affected by
laminopathy.
Immunoblot showed decreased expression of type I collagen, type III collagen,
and fibronectin with a striking increase in perk expression (Figure 11A). Each agent
showed varying degrees of effect on MAPK activity, extracellular matrix expression and
nuclear morphology (Figure 11B, Figure 12). Of the treatments, lovastatin was most
effective in rescuing the disease phenotype (Figure 11B,11C, Figure12), including the
normalization of MAPK hyperactivation, collage and fibronectin expression and nuclear
morphological changes. In future experiments, treatments will be administered to either
other isolated cell types or co-cultured depending on phenotypic results. A combination
of reagents may be used to identify their effect on cellular functionality in vitro and may
help clarify the individual or overlapping functions of these diverse signaling pathways in
heart pathology affected by the LMNA mutation. This study supports the value of using
patient-specific iPSC to explore the phenotypic perturbance caused by a diseaseassociated gene mutation and discern possible clinical therapies- “Drug-trial-in-a-dish”.
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Figure 11. Potential therapeutic target investigation in R377H-iCFs. The iCFs were
treated with selumetinib, lovastatin, ARRY797, SP600125, and everolimus for 3 weeks.
(A) Immunoblot showed decreased expression of type I collagen, type III collagen, and
fibronectin with an increase in pERK/ERK expression in LMNA-R377H iCFs compared
to wildtype iCFs. (B) Of the treatments, lovastatin was the most effective in rescuing the
ERK activation and extracellular matrix expression. (C) Quantification of immunoblot,
n=1.
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Figure 12. Nuclear morphology investigation in R377H-iCFs following treatment with
selumetinib, lovastatin, ARRY797, SP600125, and everolimus for 3 weeks. (A)
Immunostaining showed minor nuclear structure normalization at 20X in LMNA-R377H
iCFs treated with different reagents compared to vehicle DMSO treated iCFs. (B) Higher
magnification showed that lovastatin may be the most effective in rescuing the nuclear
misshape.
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RNA sequencing analysis of LMNA-iCMs
Expression variability in iCMs within and between groups
3D principal component analysis (PCA) plot showed clustering of iCM replicates
among different groups (Figure 13). While there was minor heterogeneity among the
replicates, the overall trend was that the gene expression pattern of the same group
was consistent. Different LMNA mutations have diverse gene expression patterns. It is
important to note that there is variability among the three biological controls.

Figure 13. 3D PCA plot showing clustering of iCM replicates. Seven mutated lines and
three biological control lines in triplicates are shown.
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Transcriptional profiles with up- and down-regulated genes in LMNA-iCMs
Volcano plot shows differential gene expression analysis of iCMs with different
LMNA mutations compared to control iCMs (Figure 14). Notably, different LMNA
mutations share some of the same top dysregulated genes. For example, M1I,
R216C/R399H, R216C.m, R335Q showed a significant reduction of XIST. Both M1I and
R335Q demonstrated decreased levels of CYP4F3, while decreased RPS4Y1 was
observed R377H and R541C. In terms of the upregulated genes, M1I and R216C.f
presented with increased PAX1. Increased PTN was observed R377H and R541C.
These results indicate that while molecular phenotypic variability among diverse LMNA
mutation carriers exists, different LMNA cardiomyopathy patients may share the same
interventional targets even if their genetic background is not identical.
Heatmap showed the transcriptional profiles of iCMs of individual LMNA mutation
compared to the three biological controls (Figure 15). In M1I, a direct comparison of
total RNA expression between mutant iCMs and wild-type controls exhibited a total of
4108 differentially expressed genes (DEGs), of which 2068 were upregulated and 2040
downregulated. Likewise, compared to the control iCMs, R216C/R399H-LMNA iCMs
showed 1632 upregulated and 2099 downregulated DEGs. R216C.m-LMNA iCMs
exhibited 1162 upregulated and 1905 downregulated DEGs. R216C.f revealed 2180
upregulated and 2127 downregulated DEGs. 790 upregulated and 1418 downregulated
DEGs were found in R335Q. R377H displayed1550 upregulated and 2630
downregulated DEGs. 1368 upregulated and 1748 downregulated DEGs were observed
in variant R541C iCMs. Venn diagram analyses of iCMs showed the shared and unique
differential expressed genes of LMNA variants relative to control (Figure 16).
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Figure 14. Volcano plot representing differential transcriptome of LMNA myocytes vs
control. “Upregulated” (red) or “downregulated” (blue) refers to abundance in iCMs
(control as reference). Inclusion criteria are as follows: Log2 fold change < -1, Log2 fold
change > 1 and pvalue < 0.05.
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Figure 15. Heat map representing differential transcriptome of LMNA iCMs vs three
controls. Upregulated genes are displayed in red and downregulated genes in blue.
Gene expression profiles are filtered based on the significantly differentially expressed
genes of LMNA variant compared to controls and clustered by rows (genes). Graph was
generated in R studio. Ct, control.
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Figure 15 (continued). Heat map representing differential transcriptome of LMNA iCMs
vs three controls. Upregulated genes are displayed in red and downregulated genes in
blue. Gene expression profiles are filtered based on the significantly differentially
expressed genes of LMNA variant compared to controls and clustered by rows (genes).
Graph was generated in R studio. Ct, control.
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Figure 16. Venn diagram analyses of iCMs comparing the shared and unique DEGs of
five different LMNA variants relative to controls. Inclusion criteria are as follows: Log2
fold change < -1, Log2 fold change > 1 and pvalue < 0.05.
53

Functional and pathway enrichment analysis of DEGs
Differentially expressed genes are enriched in numerous dysregulated pathways
in LMNA mutant iPSC-CMs in comparison to control LMNA-WT iPSC-CMs. Gene
Ontology in biological process, cellular component, and molecular function, KEGG, and
Reactome analysis was performed to reveal the functions of DEGs. The top 5
dysregulated terms of each approach were shown (Figure 17).
Different mutations showed specific and common pathways. The molecular
function of these DEGs was found to mostly pertain to response to protein binding,
actin-binding, cytoskeletal protein binding and ion binding via GO analysis. In the GO
biological processes analysis, the majority of DEGs was clustered within anatomical
structure morphogenesis, system development, cellular component biogenesis, mitotic
cell cycle, regulation of biological quality, response to wounding and multicellular
organism development. In the GO cellular component analysis, most DEGs were found
to be closely related to the collagen-containing extracellular matrix, external
encapsulating structure, cell junction and endoplasmic reticulum lumen, cytoplasm,
intracellular anatomical structure, and cell periphery.
KEGG pathway enrichment analysis were dilated cardiomyopathy, cAMP
signaling pathway, tight junction, cell cycle, complement and coagulation cascades and
ECM-receptor interaction. Pathways involved in platelet degranulation, regulation of
Insulin-like Growth Factor (IGF) transport, response to elevated platelet cytosolic Ca2+,
post-translational protein phosphorylation and platelet activation, signaling and
aggregation, COPI-dependent Golgi-to-ER retrograde traffic and formation of fibrin clot
(clotting cascade) were scored as the top clustered REAC.
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Figure 17. Gene expression cluster analysis of DEGs in iCMs showing top 5 pathways.
Pathways include Gene Ontology (biological process (BP), cellular component (CC),
and molecular function (MF)), Kyoto Encyclopedia of Genes and Genomes (KEGG) and
REACTOME (REAC).
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Figure 17 (continued). Gene expression cluster analysis of DEGs in iCMs showing top 5
pathways. Pathways include Gene Ontology (biological process (BP), cellular
component (CC), and molecular function (MF)), Kyoto Encyclopedia of Genes and
Genomes (KEGG) and REACTOME (REAC).
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Discussion
Laminopathies caused by abnormal mutations show a wide spectrum of
phenotypic variation. The deficiency of lamin A/C protein has been commonly studied in
animal research where the model is often homozygous. ClinVar entries for pathogenic,
likely-pathogenic, and conflicting reports of cardiovascular phenotype show that
missense mutations (197) are more frequently represented than all the
haploinsufficiency mutations (frameshift/nonsense-101, splice site-36). A clinical report
from Japan examined a cohort of symptomatic LMNA mutation carriers and found that
haploinsufficiency mutations tended to exhibit conduction system disease and DCM
earlier than those with missense mutations which suggests a potentially different
mechanism of genetic disease between these two main classes of mutation types
(Nishiuchi et al., 2017).
Our side-to-side comparison indicates that missense mutations at the start codon
and following exons can cause decreased expression of lamin A/C protein in iCMs.
Additionally, molecular disease pathways vary in iCMs dependent on different mutation
sites and types within LMNA, suggesting that the type of LMNA mutation—
haploinsufficiency or missense—yields qualitative or quantitative differences in LMNAcardiomyopathy. The disease phenotype and severity are influenced by several
parameters, including the location of the altered functional domain, the splicing outcome
of the mutation, and the mutant protein's expression level. Loss of LMNA function due to
haploinsufficiency, as well as dominant-negative or toxic gain-of-function processes
including mutations that affect heptad stability, are also possible pathogenic causes
(Captur et al., 2018).
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By attaching the linker of nucleoskeleton and cytoskeleton complex, the lamina
connects the nucleus to the cytoskeleton and thereby regulates the nuclear location,
shape, and mechanochemical signaling (Chang, Worman, & Gundersen, 2015).
Recently, Chatzifrangkeskou et al. reported abnormal activation of ERK1/2 signaling
and sarcomeric disorganization in iPSC-CMs carrying the R190W mutation. They
identified that cofilin-1 phosphorylation catalyzed by ERK1/2 altered cardiac actin
dynamics and contributed to deterioration in left ventricular function (Chatzifrangkeskou
et al., 2018). Antoku et al. also found ERK1/2 phosphorylation of formin homology
domain-containing proteins (FHOD) inhibited its actin-bundling to disrupt nuclear
positioning in cardiomyocytes expressing pathogenic lamin A/C, which established a
link between ERK1/2 and disease pathogenesis (Antoku et al., 2019). Our results have
shown that other missense mutation of LMNA causes hyperactivation of ERK pathway
and affects cardiac function differently. However, more studies are merited to reveal the
accurate association of ERK hyperactivation and cellular functional disturbances.
The structural integrity of the nuclear lamina can be compromised by either a
lack of lamin A/C or the presence of deleterious lamin A/C proteins. This instability could
disrupt nuclear mechanotransduction, leading to abnormal mechanical/electrical activity,
epigenetic alterations in chromatin, gene expression changes, DNA damage, and cell
death (S. N. Chen et al., 2019; Donnaloja et al., 2020). Cell death and apoptosis are
supported by enhanced caspase-3 activity in our iCMs, which agrees with findings from
a prior investigation of LMNA p.S143P iCMs (Shah et al., 2019).
Chatzifrangkeskou et al. documented a disruption in sarcomere structure in iCMs
with the LMNA p.R190W mutation (Chatzifrangkeskou et al., 2018). Similarly, the
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sarcomeres in our seven LMNA mutant iCM lines were severely disturbed. In the scope
of this study, the nuclear morphology and distribution of lamin A/C proteins in iCMs did
not fluctuate significantly unlike earlier studies (Shah et al., 2019; Siu et al., 2012).
Nevertheless, nuclear abnormalities were only visible after chronic stress was imposed
by electrical stimulation or ischemia in those investigations. Greater resolution imaging
like electron microscopy can be used to examine more modest nuclear envelope
abnormalities.
Arrhythmias are common in LMNA-DCM and other DCMs and altered expression
of sodium channels and connexins has been linked to them. Consistent with existing
evidence on LMNA-N195K (Mounkes, Kozlov, Rottman, & Stewart, 2005), S143P (Shah
et al., 2019), and K219T (Salvarani et al., 2019), our MEA recordings demonstrated a
diminished beating rate and conduction velocity, as well as extended FPDc and
excitation-contraction coupling, as well as a high rate of irregular calcium tracings. The
aberrant electrophysiological features we discovered among the various LMNA-iCMs
also indicate phenotypic variation among genotypes. The variability in phenotypes may
be due to differences in ion channel expression.
The major findings of RNA sequencing are the gene expression and related
pathophysiological pathway change with different mutations in LMNA. However, they
share some of the same top dysregulated genes and pathways at the same time. Both
M1I and R335Q showed a reduced level of cytochrome P450 family 4 subfamily F
member 3 (CYP4F3). CYP4F3 is associated with DCM and has been shown to affect
phosphorylation of mTOR to promote autophagy and cell death, cardiac hypertrophy
and dysfunction (Myers et al., 2019). Decreased Ribosomal Protein S4 Y-Linked 1
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(RPS4Y1) was observed R377H and R541C, in two female patients. RPS4Y1 was
previously identified to show gender-specific transcriptomic differences in new-onset
HF, coronary heart disease and ischemic cardiomyopathy (Heidecker et al., 2010; Y. Li
et al., 2018). By comparing differentially expressed genes in DCM samples with that
from healthy controls, RPS4Y1 may play a role in the development of DCM (Zhao et al.,
2018). On the other hand, augmented pleiotrophin (PTN) was observed R377H and
R541C. PTN is a growth factor that is recognized as a mitogen towards fibroblast and
inhibits apoptosis of NIH3T3 fibroblasts through activation of the MAPK pathway, which
is involved in extracellular matrix (ECM) adaptations in DCM (Louzao-Martinez et al.,
2016). In addition, previous evidence indicates that pleiotrophin promotes
cardiomyocyte cell death as a result of pro-apoptotic stress, which may be crucial to
myocardial injury repair (J. Li et al., 2007). Many DCM patients present with substantial
amounts of myocardial fibrosis, which is considered a reparative mechanism in the short
term. However, persistent and excessive myocardial fibrosis can cause arrhythmias and
heart wall stiffening (Eijgenraam, Sillje, & de Boer, 2020). Ali J Marian’s group denoted
pathogenic activation of the DDR/TP53 pathway in DCM caused by LMNAD300N, which
induced myocardial apoptosis, inflammation, fibrosis, dysregulated cell cycle
progression and cardiac dysfunction in mouse model. Previously, GEO datasets
analysis identified novel extracellular matrix changes in dilated cardiomyopathy
(Louzao-Martinez et al., 2016), in agreement with of our observations of significantly
enriched pathways including dilated cardiomyopathy, ECM-receptor interaction, and
collagen-containing extracellular matrix. Thus, we used a protocol to generate cardiac
fibroblasts to further study the pathogenesis of LMNA related cardiomyopathy.
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CHAPTER THREE
CONTRIBUTION OF CARDIAC FIBROBLAST TO LMNA-RELATED
CARDIOMYOPATHY
Introduction
Fibroblasts are highly plastic and can transdifferentiate into myofibroblasts after
tissue injury, triggering an excessive deposition of ECM and fibrosis. The pathological
fibrosis caused by activated CFs results in impaired mechanical function related to heart
failure as well as abnormal electrical activity correlated to arrhythmias and sudden
cardiac death (Kohl & Gourdie, 2014). Indeed, previous findings have shown myocardial
fibrosis impacting the cardiac conduction system in LMNA mutation carriers with
conduction deficits and arrhythmias (Arbustini et al., 2002; van Tintelen et al., 2007).
Reduced Cx43 expression and abnormal ERK1/2 were reported to trigger increased
fibrosis mediated by a mutation in lamin A/C (Chatzifrangkeskou et al., 2016; Jansen et
al., 2012). However, the level of tissue fibrosis caused by different LMNA mutations and
complete underlying mechanisms are still poorly understood. Consequently, we
assessed the activity of iPSC-derived cardiac fibroblasts at baseline and coculture
conditions with cardiomyocytes and hypothesized that their phenotypes be nonidentical
among distinctive LMNA mutation carriers.
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Methods
Generation of cardiac fibroblasts
We have adapted the Wu group’s protocol to generate cardiac fibroblasts from
iPSCs based on single-cell RNA-sequencing data (Zhang et al., 2019). Briefly, iPSCs
were cultured until 50–70% confluence. Cells were treated with RPMI basal medium
supplemented with B27-insulin (RPMI+B27-i) and CHIR99021 (6μM) for 48 hr. Then
cells were switched to RPMI with B27-i for 24 hr. For the next 48 hr, B27-i was
supplemented with IWR1 (5 μM, I0161, Sigma). From day 5 to day 8, cells were grown
in Advanced DMEM supplemented with CHIR99021 (5 μM) and retinoic acid (2 μM,
R2625, Sigma-Aldrich) and then switched to Advanced DMEM (Life Technologies) for 4
days. Cells were subsequently re-plated and cultured with fibroblast growth medium
(Cell applications) containing FGF2 (10 ng/mL, 100-18B, PeproTech) and the TGF
inhibitor, SB431542 (10 μM, S1067, Selleck chemicals) for 6 more days. For following
experiments, cells were maintained in culture with fibroblast growth media and used
until passage 5.
Wound healing assay
The migration rate of iCFs was identified using in vitro scratch assay (Liang,
Park, & Guan, 2007). In brief, cells were abraded using a pipette tip (20 μl) to generate
a groove on confluent iCF monolayer in a 6 well plate that was then gently rinsed with
PBS to remove the floating cells in the gap. Images were taken using a transmitted-light
microscope in the same areas at 0, 5, 10, 24 hr following scratch. The surfaces areas of
the openings were determined by MRI wound healing tool in ImageJ software (Suarez62

Arnedo et al., 2020). Mutant variants were compared to the average of three biological
iCF controls.
Results
Establishment of iCF model
A chemically defined differentiation protocol (Figure 18A) was employed to
generate cardiac fibroblast. By the end of 18 days of differentiation, iCFs revealed a
characteristic large, flat, elongated (spindle-shaped) fibroblast morphology, and stained
positive for fibroblast-signature marker vimentin (Figure 18B).

Figure 18. Differentiation and characterization of iPSC-derived cardiac fibroblasts
(iCFs). (A) Workflow to induce cardiac fibroblasts using small molecule-based protocols.
(B) Immunostaining of cardiac fibroblast specific marker, vimentin. Scale bar, 100 μm.

Varying expression of lamin A/C, ERK activation, and cleaved caspase-3 in
iCFs harboring different LMNA mutations
As with iCMs, we examined the hallmark molecular pathway of LMNA
cardiomyopathy in iCFs. The start codon mutation M1I conferred a particularly
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depressed expression of lamin A/C, while R377H- and R541C- iCFs exhibited a
relatively higher level of lamin A/C than the controls (Figure 19A). Of note, six of the
seven lines displayed significantly elevated ERK activation (Figure 19B) with the
exception of R355Q-iCFs. Unlike in iCMs, all different family members with LMNA
mutation demonstrated comparable levels of cleaved caspase-3 when compared to the
control iCFs (Figure 19C).

Figure 19. Variable levels of lamin A/C, extracellular signal-regulated kinase (ERK)
pathway hyperactivation, and cleaved caspase-3 in different LMNA-iCFs. (A)
Immunoblot of lamin A/C expression in iCF lines. Histogram below blots shows
normalized lamin A/C expression quantification. (B) Immunoblot of pERK1/2 (top blot)
and total ERK1/2 (middle blot) from iCFs. Histogram below blots shows pERK1/2
activation in iCFs calculated as the ratio of pERK1/2 over total ERK1/2. (C) Immunoblot
for cleaved caspase-3 from iCFs. Combined results from three controls are shown.
Results are expressed as means ± S.E.M. of three independent experiments. *p < 0.05.
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Nuclear deformity in iCFs
Previous studies on skin fibroblasts from patients affected with other LMNA
mutations have shown aberrant nuclear morphology. The mutation in LMNA didn’t
change nuclear morphology in our iCMs. Strikingly, we noted a wide range of nuclear
deformities in iCFs, such as nuclear blebbing/protrusion, nuclear invagination,
honeycomb structure and abnormal lamin A/C aggregation (Figure 20A). The nuclear
aberrancies and lamin A/C misdistribution were notably more severe in LMNA subjects
R335Q and R377H. iCFs carrying LMNA- R216C/R399H, R216C.m, R216C.f, R335Q
and R377H revealed significant reduced nuclear circularity (Figure 20B). All LMNA-iCF
lines showed perturbation of lamin A/C staining pattern that ranged from distribution
away from the nuclear membrane to areas of localized aggregation within the nuclei.
Additionally, quantification of the diverse abnormal nucleus further confirmed an
increased percentage of lamina structure impairment in all the LMNA-iCFs.
Altered cell migration in LMNA mutated iCFs
Refilling of the scratched region was measured to assess the cell migratory
capacity of iCFs in vitro (Figure 21A). Quantification demonstrated a marked decrease
in the migration rate in LMNA-iCFs at various time points (Figure 21B). A snapshot was
shown at hour 10 following “wound” was created (Figure 21C). The cell-free zone of
R355Q was greater than other variants at the end of 24 hours. This suggests that
R355Q displayed a significant reduction in cell migratorary rate than other variants.
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Figure 20. Characterization of lamin A/C nuclear morphology in iCFs. (A)
Representative immunofluorescence micrographs of lamin A/C (green) and vimentin
(red) in iCFs. Nuclei were stained with DAPI (blue). Scale bar, 10 μm. (B) Scoring of
iCFs nuclear morphology assessed by circularity (n > 100). Combined results from three
controls are shown. Data are expressed as means ± S.E.M. of two independent
experiments. *p < 0.05.
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Figure 21. Reduced migration rate in LMNA mutated-iCFs. (A) Representative images
showing diverse lines of iCFs migration at 0 h, 5 h, 10 h and 24 h. One representative
control cell line was shown. Scale bar, 200 μm. (B) Quantitative data showing reduced
migration rate in mutant-iCFs compared to control-iCFs over 24 h. (C) Histogram
showing reduced wound closure area in mutant-iCFs compared to control-iCFs at 10 h.
Combined results from three controls are shown. Data are expressed as means ±
S.E.M. of three independent experiments. *p < 0.05.
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Decreased level of connexin 43 in LMNA mutated-iCFs
qPCR and immunoblot showed that the mRNA and protein amount of Cx43 was
significantly diminished in all the mutant LMNA-iCFs in comparison to the wildtype iCFs
(Figures 22A-22C), implying that iCFs may play a vital role in the cell-cell
communication and pathophysiology of LMNA-DCM. The extent of the GJA1/Cx43
expression decrease varied among the LMNA-iCFs, the greatest being observed in M1I
and R541C.

Figure 22. Analysis of connexin 43 ion channel levels in iCFs. (A) GJA1 mRNA
quantification in different iCF lines by RT-PCR. (B) Immunoblot showing Cx43
expression in seven mutated and three control iCFs. (C) Densitometric analysis of
immunoblot showing Cx43 levels in all iCF lines. Combined results from Control #1,
Control #2 and Control #3 are shown as control. Data are expressed as means ± S.E.M.
of three independent experiments. *p < 0.05.

Amplified electrical disturbances in coculture of iCFs and iCMs carrying
LMNA mutations
We performed direct coculture experiments to assess the interplay between iCMs
and iCFs by mixing 90% iCMs and 10% iCFs from the same iPSC lines. Immunoblotting
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and qPCR showed greater downregulation of Cx43 expressions in LMNA-iCFs than in
LMNA-iCMs. Hence, we postulated that LMNA mutation adversely affects iCFs and
iCMs via Cx43-mediated gap junctions, which is partially responsible for the electrical
disturbances.
For coculture studies, we chose three LMNA mutations (M1I, R335Q, and
R541C) and three biological controls. The cardiac-specific markers α-actinin and Cx43
were visualized via co-immunostaining. Cx43 fluorescence intensity was significantly
lower in LMNA mutant patients than in wild-type controls (Figure 23). In control
coculture, Cx43 was mostly detected at cell-cell contacts, whereas in LMNA mutant
cells, it was mainly located in the cytoplasm. We examined the MEA properties of the
cocultured cells in more detail. M1I-, R335Q-, and R541C- iCM and iCF culture showed
a trend toward higher electrical disturbances when compared to iCMs alone, such as
longer beat period and FPDc, slower conduction velocity, and delayed excitationcontraction coupling (Figures 23B–E). These findings imply that LMNA-iCFs amplified
the abnormal electrical response of LMNA mutant cardiomyocytes, possibly due to
lower Cx43-mediated cell-cell communication.
Interestingly, no significant difference in Cx43 protein levels was observed in
iCMs via immunoblot (despite significant changes in transcription) whereas all LMNAiCF lines had varying degrees of reduced Cx43 protein. The addition of 10% of iCFs in
the iCM culture showed a trend towards enhanced LMNA-associated
electrophysiological abnormalities assayed on the MEA system compared to iCMs
alone, suggesting that cardiac fibroblasts interact with, and adversely affect
cardiomyocyte function in LMNA-associated DCM.
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Figure 23. Analysis of coculture of iCMs and iCFs. (A) Representative
immunofluorescence images of α-actinin (red), and connexin 43 (green) of iCMs and
iCFs coculture from one representative control and three mutants M1I, R335Q, R541C.
Nuclei stained with DAPI (blue). Scale bar, 10 μm. Bar graphs of (B) Beat Period, (C)
FPDc, (D) Conduction velocity, (E) E-C delay (Excitation-contraction delay) of iCMs
alone and coculture; n = 3 wells per group. Combined results from Control #1, Control
#2 and Control #3 are shown as control. Data are expressed as means ± S.E.M. of
three independent experiments. *p < 0.05.
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RNA sequencing analysis of LMNA-iCFs
Expression variability in iCFs within and between groups
3D PCA plot showed clustering of iCF replicates among different groups (Figure 24).
While there was minor heterogeneity among the replicates, the overall trend was that
the gene expression pattern of the same group was consistent. Different LMNA
mutations exhibited diverse gene expression patterns. It is important to note that there
was variability among the five biological controls.

Figure 24. 3D PCA plot showing clustering of iCF replicates. Seven mutated lines (all in
triplicate) and five biological control lines (four in duplicate and one in singleton) are
shown.
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Up- and down-regulated genes in various LMNA mutated iCFs
Volcano plot showed differential gene expression analysis of iCFs with distinct
LMNA mutations compared to control iCFs (Figure 25). Notably, different LMNA
mutations shared some of the same top dysregulated genes. For example, UNC45B
(UNC45 myosin chaperone B) was downregulated in M1I, R216C/R399H, R216C.f and
R377H. CASQ2 (calsequestrin 2) is by far the most abundant calcium-binding protein
that acts as a calcium buffer within the sarcoplasmic reticulum. It was found to be
reduced in M1I, R216C.f and R541C. Both KCNA1 (potassium voltage-gated channel
subfamily A member 1) and MYOD1 (myogenic differentiation 1) were downregulated in
M1I and R216C.f. R377H and R541C showed decreased RPS4Y1 (ribosomal protein
S4 Y-linked 1). On the other hand, MEG3 (maternally expressed 3) was universally
increased in M1I, R216C/R399H, R216C.f, R377H and R541C. P2RY8 (P2Y receptor
family member 8) was found to be increased in R216C/R399H, R216C.m. GJB2 (gap
junction beta-2 protein) was upregulated in R216C.m and R335Q. ASNSP1 (asparagine
synthetase pseudogene 1) was higher in R216C.m, R216C.f and R541C.
P2Y receptor family member 8 (P2RY8), gap junction beta-2 protein (GJB2) and
asparagine synthetase-like 1 (ASNSP1) have not been reported previously to be
implicated in cardiomyopathy and may represent novel contributors to LMNA
pathophysiology in a mutation-specific fashion. The significance of other top
dysregulated genes has been described before and will be further disscussed below.
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Figure 25. Volcano plot representing differential transcriptome of different LMNA-iCFs
vs controls. “Upregulated” (red) or “downregulated” (blue) refers to abundance in iCFs
(control as reference). Inclusion criteria are as follows: Log2 fold change < -1, Log2 fold
change > 1 and pvalue < 0.05.
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Transcriptional profiles of LMNA mutant iCFs
Like iCMs, we also found DEGs showing different transcriptional profiles in
LMNA mutated iCFs compared to five wildtype iCFs (Figure 26). A total of 992 DEGs
with 312 up-regulated and 680 down-regulated genes were thus identified in M1I-iCFs.
Compared to control iCFs, R216C/R399H-LMNA iCFs showed 969 upregulated and
1027 downregulated DEGs. The son of subject R216C/R399H, R216C.m-LMNA iCFs
exhibited 191 upregulated and 456 downregulated DEGs. R216C.f revealed 419
upregulated and 985 downregulated DEGs. 272 upregulated and 667 downregulated
DEGs were found in R335Q. R377H displayed 491 upregulated and 783 downregulated
DEGs. 605 upregulated and 1349 downregulated DEGs were observed in variant
R541C-iCFs. Overall, the counts of DEGs in iCFs are fewer than that in iCMs for the
identical mutations.
Venn diagram analyses of iCFs showed the shared and unique differential
expressed genes of five different LMNA variants relative to control (Figure 27). In
iCMs,there are 273 differential expressed genes that are commonly shared among
these 5 vairants. In this case, there are only 11 differential expressed genes that are
commonly shared among these 5 iCF vairants. It would be of great interest to screen
these 11 genes in order to explore the possibility of finding highly sensitive and
ubiquitous interventional targets that could be of benefit to patients carrying diverse
LMNA mutations.
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Figure 26. Heat map representing differential transcriptome of LMNA mutated iCFs vs
controls. Upregulated genes are displayed in red and downregulated genes in blue.
Gene expression profiles are filtered based on the significantly differentially expressed
genes of LMNA variant compared to controls and clustered by rows (genes). Graph was
generated in R studio. Ct, control.
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Figure 27. Venn diagram analyses of iCFs comparing the shared and unique DEGs of
five different LMNA variants relative to controls. Inclusion criteria are as follows: Log2
fold change < -1, Log2 fold change > 1 and pvalue < 0.05.
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Functional and pathway enrichment analysis of DEGs in iCFs
We then performed functional enrichment analyses and meaningful pathways
enrichment analyses on iCFs based on the DEGs for each mutation. Gene Ontology in
BP, CC, and MF, KEGG, and REAC analysis were performed to reveal the functions of
DEGs. The top 5 dysregulated terms of each analysis were shown (Figure 28). In the
GO analysis, the clustered molecular function pathways were mostly the extracellular
matrix structural constituent, collagen binding, calcium ion binding, protein binding,
amyloid-beta binding peptide binding, and gated channel activity. The enriched
biological processes were associated with multicellular organism development,
developmental process, nervous system development, anatomical structure
morphogenesis, cell-cell signaling and biological adhesion. In the GO cellular
component analysis, most DEGs were found to be closely related to the extracellular
matrix, external encapsulating structure, collagen-containing extracellular matrix, cell
periphery, an intrinsic component of the plasma membrane and cell junction. KEGG
pathway enrichment analysis identified significantly enriched pathways such as
complement and coagulation cascades, PI3K-Akt signaling pathway, calcium signaling
pathway, protein digestion and absorption, cell adhesion molecules, dilated
cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic right ventricular
cardiomyopathy. REAC identified pathways involved in the extracellular matrix
organization, molecules associated with elastic fibers, collagen formation and collagen
degradation.
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Figure 28. Gene expression cluster analysis of DEGs from iCFs showing top 5
pathways. Pathways include Gene Ontology (biological process (BP), cellular
component (CC), and molecular function (MF)), Kyoto Encyclopedia of Genes and
Genomes (KEGG) and REACTOME (REAC).
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Figure 28 (continued). Gene expression cluster analysis of DEGs from iCFs showing
top 5 pathways. Pathways include Gene Ontology (biological process (BP), cellular
component (CC), and molecular function (MF)), Kyoto Encyclopedia of Genes and
Genomes (KEGG) and REACTOME (REAC).
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Discussion
Given the ample lamin A/C expression in cardiac fibroblasts and endothelial
cells, LMNA mutation is likely to adversely affect molecular signaling and cell function in
one or more of the non-myocyte cell types. Using specific differentiation protocols, we
identified that as in iCMs, iCFs also showed phenotypic and mechanistic heterogeneity
underlying distinctive LMNA mutation at the molecular and functional levels. Multiple
hypotheses were considered to explain the pathophysiological processes of cardiac
laminopathies. Mutant lamin A/C protein is considered to cause three general types of
pathology: nuclear instability, aberrant gene expression, and cell toxicity. Each are
possibly contributory and non-exclusive.
In the structural hypothesis, nuclear lamina is connected to the extracellular
matrix and sustains the cellular structural integrity by cytoskeletal networks. In
fibroblast, the stress resilience, force transmission and hypertrophic response to
pressure load are all compromised by LMNA mutations (Antoku et al., 2019). In our
project, the nuclear deformity was more readily evident in the LMNA-iCF lines than in
the LMNA-iCM lines. Fibroblasts are highly plastic and can transdifferentiate into
myofibroblasts after tissue injury, triggering an excessive deposition of ECM, fibrosis
and increased migratory rate. The decreased fibroblast migration rate observed in our
study is not contradictory to possible enhanced fibrosis, given the fact that the
cytoskeleton disruption caused by LMNA mutations may hinder actin bundling and
disturb nuclear location. As a result, nuclear anchorage, mechanical sensing, and
structural resistance can be impaired. LGE-CMR can identify myocardial fibrosis under
genetic control in vivo in patients with heritable lamin cardiomyopathy (Raman et al.,
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2007). Cardiac ERK1/2 activity is described to mediate fibrosis and alter the cardiac
function of LMNA cardiomyopathy in mouse models, which can be alleviated by MAPK
inhibitor (Arimura et al., 2005; Chatzifrangkeskou et al., 2016; Raman et al., 2007; Wu
et al., 2011). We depicted that fibroblasts may contribute to cardiac pathology via
abnormal hyperactivation of the ERK pathway in several LMNA mutations.
In the gene expression hypothesis, the nuclear envelope is involved in tissuespecific gene expression, which can be negatively affected by LMNA mutations.
Pathways such as Rb/E2F or Rb/MyoD, TGF-β and WNT/β-catenin, and CTGF/CCN2
cascades are implicated in cardiac remodeling and are regulated by lamins' interactions
with nuclear envelope proteins and transcription factors (Bernasconi et al., 2018;
Chatzifrangkeskou et al., 2016; Dorner, Gotzmann, & Foisner, 2007; Frock et al., 2006;
Le Dour et al., 2017; Melcon et al., 2006; Worman, 2018). Through Dusp4 expression,
they also influence the MAPK and AKT/mTOR pathways (Choi, Wu, et al., 2012). JNK
branch of MAPK pathway has been shown to alter connexin protein expression (Petrich
et al., 2002; Ursitti et al., 2007), which corresponds to our observation of MAPK
activation and connexin reduction.
The precise mechanisms of increased beating variability in vitro are unknown,
however, our findings point to changes in ion channel and calcium-related gene
expression as a contributing component. Regardless of considerable alterations in
transcription, no significant difference in Cx43 protein expression was identified in iCMs
using immunoblot. But all LMNA-iCF lines had differing levels of decreased Cx43
protein, suggesting that dysregulated fibroblastic Cx43 expression is a key mediator for
arrhythmogenicity on top of iCMs. We cocultured iCFs with iCMs from the same iPSC
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source cell line to illustrate the involvement of LMNA-iCFs in LMNA-DCM. In
comparison to iCMs alone, adding 10% of iCFs to the iCM culture resulted in a trended
increase in electrophysiological deficits as measured on the MEA system, implying that
mutant cardiac fibroblasts interact with and negatively influence the functionality of
cardiomyocytes.
In the cell toxicity hypothesis, LMNA mutations impede cardiomyocyte autophagy
via activating the AKT/mTOR pathway, leaving the cell prone to oxidative stress and/or
the buildup of harmful misfolded or farnesylated lamins (Choi, Muchir, et al., 2012).
Temsirolimus aids mutant protein elimination through autophagy (Choi & Worman,
2013). It would be of interest to exam the autophagy markers in both iCMs and iCFs.
Apoptosis is used to select cells during normal physiological functions, also during
toxicities and diseases. Our mutant fibroblast didn’t present with increased apoptosis
like that in the iCMs, possibly due to active proliferation and higher turnover rate.
Interestingly, we observed atypical projection of lamin A/C out of the nuclear membrane
into the cytoplasm in R355Q- and R377H-iCFs. It is possible that reduced lamin function
could lead to its overexpression, nuclear occupancy site exhaustion, and detrimental
translocation to the cytosol (Schreiber & Kennedy, 2013).
Importantly, we identified a few significantly dysregulated genes in LMNA
mutated cardiac fibroblasts. For example, UNC45B is found to be downregulated in M1I,
R216C/R399H, R216C.f and R377H. UNC45B is a key molecular chaperone that plays
a crucial role in stabilizing myosin, ensuring normal sarcomeric structures and
contractility and thus preventing human cardiomyopathy (C. F. Lee et al., 2011; Melkani,
Bodmer, Ocorr, & Bernstein, 2011). Calsequestrin (CASQ2) is reduced in M1I, R216C.f
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and R541C. Calsequestrin has been extensively associated with calcium mishandling in
tachyarrhythmias (both atrial and ventricular) (Faggioni & Knollmann, 2012). MYOD1,
also known as myoblast determination protein 1, is a protein in animals that plays a
major role in regulating muscle differentiation. Contrary to the upregulation of MYOD1
described in skeletal muscle from Lmna H222P/H222P and LMNA-knockout mice
(Mejat et al., 2009), we observed a downregulated in M1I and R216C.f. It is noteworthy
that like in iCMs, R377H- and R541C-iCFs also showed decreased RPS4Y1. Global
lncRNA profiling has linked lncRNA maternally expressed gene 3 (MEG3) to MMP-2
production by CFs in vitro and in vivo, indicating its role in cardiac fibrosis and cardiac
remodeling (Piccoli et al., 2017). MEG3 knockdown has shown benefits in protecting
human cardiomyocytes from HG-induced apoptosis and diabetic cardiomyopathy
development (Chen, Zhang, Zhu, Zhao, & Li, 2019).
Most DEGs in LMNA mutated iCFs were found to be closely related to the
extracellular matrix organization pathway, further reinforcing the role of cardiac
fibroblast in fibrosis in cardiac laminopathies. Disruption of extracellular matrix
homeostasis has been defined as an important contributor to the development of left
ventricular remodeling and dysfunction (Pauschinger et al., 2002). Specifically, the
collagen-containing extracellular matrix was identified to be a crucial enrichment term.
Collagens I and III are the most critical proteins that lead to cardiac distensibility. Type I
is sturdier and more comparable to steel, whereas type III is more pliable. In healthy
heart muscle, the ratio of type III to type I is typically steady and can be used as a
measure of myocardial distensibility. At early phases of cardiomyopathy, the collagen
III:I ratio rises (21,22). Persistent cardiac fibrosis in late stages of cardiomyopathy, on
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the other hand, is characterized by a predominance of collagen type I (22–26) buildup
and a lower collagen III:I ratio (Kapelko, 2001). The collagen structure is a balance
between protein synthesis and breakdown. The specific enzyme intercellular
collagenase, matrix metalloproteinase-1 (MMP-1) is the main type to break down
collagens into two fragments, which are then broken down further by gelatinases MMP2 and MMP-9. Correspondingly, our data suggest that there are alterations in collagen
binding, collagen formation and collagen degradation. Future studies should be
designed to investigate the expression profile of specific collagens and enzymes
implicated in the degradation of collagens.
We also observed enrichment of dysregulated genes in the PI3K/AKT signaling
pathway in M1I and R335Q. PI3K/AKT signaling pathway is found to stimulate mTORC1
by growth factors and cytokines. Interestingly, abnormal activation of protein kinase B
(AKT)/mTOR signaling was described in muscular laminopathies (Chiarini et al., 2019;
Choi, Muchir, et al., 2012), and normalization of mTOR-regulated pathways rescues
cardiac and skeletal muscle function, improves life expectancy in lamin A/C-deficient
mouse models (Chiarini et al., 2019; Choi & Worman, 2013; Ramos et al., 2012).
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CHAPTER FOUR
CONCLUSIONS AND PERSPECTIVES
To investigate how various LMNA-cardiomyopathy mutations influence behaviors
of cardiomyocytes and non-cardiomyocytes within the heart and their contribution to
cardiac pathogenesis, we successfully generated iPSC-derived cardiomyocytes and
cardiac fibroblasts to model LMNA related DCM. Detailed comparisons and
characterization of iCMs and iCFs are summarized in table 4 and table 5. The important
phenotypic variabilities are concluded below: diverse missense mutations in LMNA
resulted in the distinct level of lamin A/C expression and ERK pathway activation in
iCMs and iCFs. LMNA mutations were associated with sarcomere disarray in iCMs and
lamina misshape in iCFs. Enhanced apoptosis was shown in LMNA-related DCM-iCMs
than DCM-iCFs. A reduction of cell migration rate was observed in LMNA mutant
fibroblasts. LMNA mutation caused conduction defects and calcium mishandling,
possibly linked to the ion channel and connexin 43 expressions.
To investigate gene expression differences for various LMNA-CM mutations, we
performed RNA sequencing to characterize the transcriptomic profiles of iCMs and iCFs
induced from different patients.
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Table 4. Phenotype comparison of iCMs carrying different LMNA mutations.

Symbol  indicates an increase;  decrease;  no significant change; MEA indicates microelectrode array; EAD early
afterdepolarization; Oscil/Fib oscillations/fibrillations; FPDc rate-corrected Field potential duration; CV Conduction velocity;
E-C delay Excitation contraction delay
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Table 5. Phenotype comparison of iCFs carrying different LMNA mutations.
Subject
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A/C
protein
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Cx43
protein

Nuclear Migration
circularity
rate

Symbol  indicates an increase;  decrease;  no significant change
Our RNA seq-based differential gene expression analysis showed that LMNAsubject replicates clustered together by principal components. There were large
numbers of genes and pathways that were commonly and differentially expressed
among the different LMNA subject-iCMs and iCFs (Figure 29-30). This preliminary data
is encouraging for further pursuit of this hypothesis that different LMNA mutations
produce variable early phenotypes. Notably, RNA-seq showed differentially expressed
genes with significant enrichment in extracellular matrix organization both in iCMs and
iCFs. Taken together, this head-to-head evaluation of many patient-specific LMNA
mutations under the same conditions and in the same laboratory is a novel approach
that will enable a more accurate assessment of true differences exerted by different
LMNA mutations, which could provide unique insights into Precision Medicine of human
LMNA-related DCM.
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Figure 29. Heat map of dysregulated pathways compared across the different LMNAiCMs.

Figure 30. Heat map of dysregulated pathways compared across the different LMNAiCFs.
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Each disease model system has its benefits and drawbacks, which provide
complementary insights into disease mechanisms and treatment options. Our iPSC
technique has various advantages, including patient specificity, time, cost, and species
relevance (Milani-Nejad & Janssen, 2014). Moreover, it allows us to discern cell-type
specificity and inform the discovery of personalized therapeutic targets. However, it's
also crucial to recognize the limits of our method. Although iCMs are believed to mimic
adult human cardiomyocytes, they have less mature characteristics (Karbassi et al.,
2020). Phenotypic variations among the LMNA cell lines could be attributable to distinct
mutation locations, but the genetic background could also play a role.
To address these potential issues, isogenic lines are necessary to thoroughly
investigate the consequences of a genetic mutation. We will employ CRISPR-Cas9
techniques to modify the genes of these cell lines (Anzalone et al., 2019). Continuous
electrical stimulation, 3D culture, and prolonged culture can be applied to accelerate the
process of iCM maturation (Ahmed, Anzai, Chanthra, & Uosaki, 2020). Further research
on the fibrosis pathway, the direct/indirect interaction between iCMs and iCFs, and the
role of endothelial cells and macrophages produced from iPSCs in the development of
LMNA-related cardiomyopathy is needed. Additionally, our iPSC system can be used as
a model for in vitro drug screening. Several medications (selumetinib, lovastatin,
ARRY797, SP600125, and everolimus) have been shown to show benefits targeting
different molecular phenotypes. We propose to compare the efficacy of these drugs
alone and in combination in rescuing the observed abnormalities in iCMs and iCFs
carrying different LMNA mutations respectively and in coculture systems.
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Particularly, our RNA-seq data identified several important DEGs that serve as
potential intervention targets for future studies. For instance, increased PTN
(pleiotrophin) was observed R377H-iCMs and R541C-iCMs. Pleiotrophin is a cytokine
that regulates angiogenesis, cell proliferation, and differentiation, and has been shown
to inhibit UV-induced apoptosis via knockdown of PTN by siRNA in neonatal
cardiomyocytes (J. Li et al., 2007). PTN has also been shown to be up-regulated early
during the in vitro formation of cardiomyocytes from iPSCs and in human hearts with left
ventricle assist device (Anisimov, Tarasov, Riordon, Wobus, & Boheler, 2002; Margulies
et al., 2005). Wang et al. reported that PTN transcripts are significantly increased in
atrial natriuretic factor-null mice subjected to pressure overload (D. Wang et al., 2003).
Future experiments can be designed to investigate whether the knockdown of
endogenous PTN could inhibit the apoptotic response of LMNA mutant iCMs. Posttranscriptional gene silencing by siRNA interference of PTN expression can be
performed by using chemically synthesized duplex RNA oligonucleotides against PTN
(J. Li et al., 2007).
In iCFs, UNC45B is found to be downregulated in M1I, R216C/R399H, R216C.f
and R377H. UNC45B acts as a co-chaperone for HSP90 and is required for proper
folding of the type II myosin motor domain and its accumulation. Type II myosin plays a
crucial role in sarcomere formation during muscle cell development and cardiomyopathy
(C. F. Lee et al., 2011; Melkani et al., 2011). The pathogenic variants of UNC45B have
been shown to cause myopathy (Dafsari et al., 2019; Donkervoort et al., 2020; Myhre &
Pilgrim, 2012). Non-muscle cell myosin II is found in contractile bundles called stress
fibers and plays an active part in cell adhesion and migration (Vicente-Manzanares, Ma,
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Adelstein, & Horwitz, 2009). Since we observed a reduction of fibroblast migration,
overexpression of UNC45B by in vitro mRNA or plasmid DNA transfection can be
employed to rescue the cellular phenotype. Endothelial cells (EC) appear to be the most
common non-myocyte cell type (estimates often above 60%) (Bergmann et al., 2015;
Pinto et al., 2016; P. Zhou & Pu, 2016). The Wu group has recently shown that iECs
from LMNA patients are adversely affected in vasculature and cardiomyocytes with
aberrant KLF2 signaling (Sayed et al., 2020). We will incorporate iPSC-derived
endothelial cells (MacAskill et al., 2018) into our co-culture system to study how LMNAACM mutations influence behaviors of endothelial cells within the heart and the
endothelial-myocardial signaling in cardiac pathogenesis.
While this is not always feasible for every mutation site and type, we are in the
process of generating isogenic controls through CRISPR-Cas9 of the LMNA-iPSC lines
we have generated. We are employing gRNA and Cas9 constructs containing a
puromycin selectable marker (Mali et al., 2013; L. Yang, Mali, Kim-Kiselak, & Church,
2014). Mutations are not uncommon in CRISPR-Cas9 gene editing (Fu et al., 2013) so
edited cells will go through rounds of sorting and dilution to obtain multiple clones that
will be assayed by sequencing for off-target mutations. Alternatively, prime editing with
much lower off-target editing than Cas9 nuclease (Anzalone et al., 2019). Successful
optimization and analysis will inform CRISPR-Cas9 or prime editing as potential longlasting therapy.We anticipate that after the identification of genes and pathways that are
potential therapeutic candidates we will then proceed to further validation in animal
(transgenic mouse models). This will be necessary once compounds or therapies are
validated in the iPSC system.
91

CHAPTER FIVE
USE OF HUMAN IPSC-DERIVED CARDIOMYOCYTE MODELS TO STUDY THE
CARDIOPATHOGENESIS OF THE PROTOZOAN PARASITE, TOXOPLASMA
GONDII
Introduction
Toxoplasmosis is caused by Toxoplasma gondii (T. gondii), a parasite with a high
prevalence in tropical regions. It spreads to humans either by consumption of
undercooked meat, contaminated water, or by contact with feline feces. Toxoplasmosis
can be transmitted from person-to-person in case of congenital transmission and organ
transplantation (Hermanns et al., 2001; Kirchhoff, Weiss, Wittner, & Tanowitz, 2004;
Nicoloso, Henke, & Zielinsky, 2004; Robert-Gangneux, Amrein, Lavarde, Botterel, &
Dupouy-Camet, 2000). Even though the majority of infections present with very minor
symptoms, those who are immunocompromised have a dismal prognosis following
opportunistic infections. Cardiovascular symptoms of toxoplasmosis are uncommon and
have only been recorded in a small number of cases. Opportunistic cardiac
toxoplasmosis is mainly characterized by myocarditis and can cause complications
including arrhythmias, heart failure, cardiomyopathies, and cardiac arrest, resulting in
significant morbidity and mortality (Bal, Dhooria, Agarwal, Garg, & Das, 2014; Hofman,
Drici, Gibelin, Michiels, & Thyss, 1993).
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Because cardiovascular implications in toxoplasmosis are uncommon and
frequently asymptomatic or disguised by neurological impairment (Hidron et al., 2010;
Hofman et al., 1993), the impacts of toxoplasmosis on the heart have not been
extensively researched. While minor forms of toxoplasmosis in immunocompetent hosts
usually resolve on their own, more progressive manifestations in patients with human
immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) or other
immunosuppressive disorders might have serious consequences (Pergola, Cascone, &
Russo, 2010; Z. Zhou et al., 2021). However, the presence of myocardial lesions was
not identified till the time of necropsy (Hofman et al., 1993). Therapeutic approaches are
directed at managing the outcomes of disease such as cardiac failure, which imposes
needs for effective diagnosis, treatment, and clinical management at an early stage of
infections. To this end, in vitro generated cardiomyocytes derived from human induced
pluripotent stem cells have provided us a valuable tool for understanding the
progression of parasitic infection and standardization of models designed for cardiac
toxoplasmosis drug discovery.
Methods
Toxoplasma gondii infection
Toxoplasma gondii TypeI/III EGS strain (dual fluorescent stage-specific reporter
strain with mCherry driven by the tachyzoite specific SAG1 promoter and sfGFP driven
by the bradyzoite-specific LDH2 promoter) was a gift from Dr. Louis Weiss (Albert
Einstein College of Medicine). The EGS tachyzoites were maintained in human foreskin
fibroblasts (HFFs) grown in Dulbecco’s modified Eagle medium (DMEM; Life
Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies),
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2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C with 5%
CO2.
ATCC iPSC 1029 cell line were differentiated into cardiomyocytes, cardiac
fibroblasts and neurons as previously described. Confluent iPSC-CMs, iPSC-CFs,
iPSC-Neurons and human foreskin fibroblasts (hFFs) in 6-well plates were infected with
T. gondii EGS strain at a multiplicity of infection of two tachyzoites per cell. At 24 hours
and 72 hours post-infection, uninfected and T. gondii-infected cells were washed with
phosphate-buffered saline (PBS) and the cell monolayers were scraped into TRIzol
(Invitrogen) for total RNA extraction. 1 ug of total RNA was sent for RNA sequencing at
Novogene.
Results
In our current work, human induced pluripotent stem cell-derived cardiomyocytes
(iCMs), cardiac fibroblasts (iCFs) and neurons (iNEs) have been used as biologically
relevant models to study the interactions of T. gondii with human hosts in vitro. iCMs,
iCFs and iNEs can be infected with T. gondii TypeI/III EGS strain (dual fluorescent
stage-specific reporter strain with mCherry driven by the tachyzoite-specific SAG1
promoter and sfGFP driven by the bradyzoite-specific LDH2 promoter) and can support
parasite development. We observed a higher rate of bradyzoite formation in iCMs,
compared to iCFs from the same donor or HFF at 72 hours post-infection by flow
cytometry (Figure 31).
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Figure 31. Flow cytometry showing percentage of tachyzoite and bradyzoite formation in
iPSC-CM, iPSC-CF and HFF infected with T. gondii TypeI/III EGS strain for 24 hours
and 72 hours.

Expression variability of T. gondii EGS strain infected cells within and
between groups
PCA plot showed clustering replicates of iPSC induced cardiomyocytes (CMs),
iPSC induced cardiac fibroblasts (CFs) and iPSC induced neurons (NEs) infected with
T. gondii EGS strain for 24 hours (Inf24CM, Inf24CF, Inf24NE) and 72 hours (Inf72CM,
Inf72CF, Inf72NE) in comparison to the uninfected controls (UninfCM, UninfCF,
UninfNE) (Figure 32). While there was minor heterogeneity among the replicates, the
overall trend was that the gene expression pattern of the same cell type at the same
infection time point was consistent. Infection for 72 hours shifted gene expression
patterns compared to the 24-hour-infection or the uninfected cells.
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Figure 32. PCA plot showing clustering of iPSC induced cells infected with T. gondii
EGS strain. IPSC induced cardiomyocytes (CMs), iPSC induced cardiac fibroblasts
(CFs) and iPSC induced neurons (NEs) were infected with T. gondii for 24 hours
(Inf24CM, Inf24CF, Inf24NE) and 72 hours (Inf72CM, Inf72CF, Inf72NE) in comparison
to the uninfected controls (UninfCM, UninfCF, UninfNE) (n=3).

Up- and down-regulated genes in iCMs infected with T. gondii EGS strain
for 24 hours and 72 hours
Volcano plot shows differential gene expression analysis of iCMs infected with T.
gondii EGS strain for 24 hours and 72 hours compared to uninfected iCMs (Figure 33).
Notably, infected iCM for 24 hours and 72 hours share some of the same top
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dysregulated genes. For example, significantly upregulated genes in common include
SLC6A14, IL18R1, CXCL8, BIRC3, HAS2. Significantly downregulated genes in
common include PODXL, ACTA2, CCND1.

Figure 33. Volcano plot representing differential transcriptome of iCMs infected with T.
gondii EGS strain for 24 hours and 72 hours vs uninfected iCMs. “Upregulated” (red) or
“downregulated” (blue) refers to abundance in iCMs (uninfected as reference). Inclusion
criteria are as follows: Log2 fold change < -1, Log2 fold change > 1 and pvalue < 0.05.

Transcriptional profiles of iCMs infected with T. gondii EGS strain for 24
hours and 72 hours
Consistent with the volcano plot, the heatmap showed the transcriptional profiles
of iCMs infected with T. gondii EGS strain for 24 hours and 72 hours compared to
uninfected iCMs (Figure 34). A direct comparison of total RNA expression between
infected iCMs for 24 hours and uninfected controls exhibited a total of 1843 differentially
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expressed genes (DEGs), of which 1090 were upregulated and 753 downregulated.
Likewise, compared to uninfected iCMs, infected iCMs for 72 hours showed 1956
upregulated and 1253 downregulated DEGs.

Figure 34. Heat map representing differential transcriptome of iCMs infected with T.
gondii EGS strain for 24 hours and 72 hours vs uninfected iCMs. Upregulated genes are
displayed in red and downregulated genes in blue. Gene expression profiles are
clustered by rows (genes).

Functional and pathway enrichment analysis of DEGs in iCMs infected with
T. gondii EGS strain for 24 hours and 72 hours
Differentially expressed genes are enriched in numerous dysregulated pathways
in iCMs infected with T. gondii EGS strain for 24 hours and 72 hours in comparison to
control uninfected iCMs. Gene Ontology, KEGG, and Reactome analysis were
performed to reveal the functions of DEGs. The top dysregulated terms of each
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approach were shown in the dot plot (Figure 35). Both 24-hour and 72-hour postinfection iCMs demonstrated important GO terms in signaling receptor activity,
sarcomere structure machinery, extracellular matrix and cytokine activity, main KEGG
terms associated with PI3K-Akt signaling pathway and cytokine-cytokine receptor
interaction, as well as essential Reactome pathways such as signaling by interleukin,
GPCR ligand binding and extracellular matrix organization.
Transcriptional profiles with up- and down-regulated genes of iCFs infected
with T. gondii EGS strain for 24 hours and 72 hours
Volcano plot shows differential gene expression analysis of iCFs infected with T.
gondii EGS strain for 24 hours and 72 hours compared to uninfected iCFs (Figure 36).
Notably, iCFs infected for 24 hours and 72 hours share some of the same top
dysregulated genes. For example, significantly upregulated genes in common include
KCNK3, TFPI2, COL5A3, CCL26. Significantly downregulated genes in common
include INMT, FMO1, TXNIP, ASPN, TMEM119.
Consistent with the volcano plot, the heatmap showed the transcriptional profiles
of iCFs infected with T. gondii EGS strain for 24 hours and 72 hours compared to
uninfected iCFs (Figure 37). A direct comparison of total RNA expression between
infected iCFs for 24 hours and uninfected controls exhibited a total of 3625 differentially
expressed genes (DEGs), of which 1654 were upregulated and 1971 downregulated.
Likewise, compared to uninfected iCFs, infected iCFs for 72 hours showed 2742
upregulated and 1916 downregulated DEGs.
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Figure 35. Gene expression cluster analysis of DEGs from iCMs infected with T. gondii
EGS strain for 24 hours and 72 hours vs uninfected iCMs. Upper panel: Gene Ontology,
middle panel: KEGG, lower panel: Reactome.
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Figure 36. Volcano plot representing differential transcriptome of iCFs infected with T.
gondii EGS strain for 24 hours and 72 hours vs uninfected iCFs. “Upregulated” (red) or
“downregulated” (blue) refers to abundance in iCFs (uninfected as reference). Inclusion
criteria are as follows: Log2 fold change < -1, Log2 fold change > 1 and pvalue < 0.05.

Figure 37. Heat map representing differential transcriptome of iCFs infected with T.
gondii EGS strain for 24 hours and 72 hours vs uninfected iCFs. Upregulated genes are
displayed in red and downregulated genes in blue. Gene expression profiles are
clustered by rows (genes).
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Functional and pathway enrichment analysis of DEGs in iCFs infected with
T. gondii EGS strain for 24 hours and 72 hours
Differentially expressed genes are enriched in numerous dysregulated pathways
in iCFs infected with T. gondii EGS strain for 24 hours and 72 hours in comparison to
control uninfected iCFs. Gene Ontology, KEGG, and Reactome analysis were
performed to reveal the functions of DEGs. The top dysregulated terms of each
approach were shown in the dot plot (Figure 38). Both 24-hour and 72-hour postinfection iCFs demonstrated important GO terms in the extracellular matrix. Key KEGG
terms at 24-hour infection were associated with the ribosome and oxidative
phosphorylation whereas 72-hour infection KEGG terms showed PI3K-Akt signaling
pathway and cytokine-cytokine receptor interaction, similar to that in the 72-hour
infected iCMs. Primary Reactome terms at 24-hour infection were signaling by ROBO
receptors. 72-hour infection KEGG terms were predominantly related to signaling by
receptor tyrosine kinases, signaling by interleukin, and extracellular matrix organization.
To investigate iPSC-CFs, enrichment analysis was performed and highlighted
extracellular matrix organization and cytokine-cytokine receptor interaction pathway. For
future directions, we will analyze the secretion of cytokines and chemokines and fibrosis
markers by iCFs following T. gondii infection. Importantly, we observed significant
enrichment in oxidative phosphorylation. We will utilize seahorse to measure glycolysis
by analyzing the extracellular acidification rate and assess mitochondrial oxidative
phosphorylation on the basis of the oxygen consumption rate.
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Figure 38. Gene expression cluster analysis of DEGs from iCFs infected with T. gondii
EGS strain for 24 hours and 72 hours vs uninfected iCFs. Upper panel: Gene Ontology,
middle panel: KEGG, lower panel: Reactome.
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Discussion and future directions
Uninfected and T. gondii EGS strain-infected samples were grouped separately
according to PCA analysis, which showed variability in gene expression before and after
T. gondii infection. The potential of T. gondii EGS strain to invade iPSC-CMs was
verified by flow cytometry after 24 and 72 h interaction, in ratios of 1:2 (iPSCCMs/CFs/Neurons: parasites), respectively. The volcano plot and heatmap showed a
differential gene expression pattern. Gene enrichment assay showed potential cytokines
and chemokines secreted by iPSC-CMs following T. gondii infection. Although CMs do
not typically produce cytokines and chemokines, this finding suggested the potential
inflammation in cardiac toxoplasmosis. GO enrichment showed disruption in sarcomere
machinery, Z disc, I band, contractile fiber, which might correlate with morphology
changes and the advent of iPSC-CM dysfunction. Interestingly, 72-hour infection
triggered more DEGs than the 24-hour infection, corresponding to an increase in
tachyzoite formation at 72 hours following infection. In future experiments, we will
examine the sarcomere structure, pro-inflammatory markers and functionality in iCMs
infected with T. gondii for 72 hours. Further study will validate and highlight a list of
relevant genes that might play an important role in toxoplasmosis pathogenesis, making
them potential targets for pharmacological intervention.
Our study generates the first compelling data to demonstrate the feasibility of
using human iPSCs to model toxoplasmosis. A detailed analysis of validation and
intervention of the top dysregulated genes in all different cell types will inform the design
of potential novel therapeutic targets against toxoplasmosis.
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APPENDIX I:
LIST OF ABBREVIATIONS
CM ············· cardiomyopathy
HCM ·········· hypertrophic cardiomyopathy
DCM ·········· dilated cardiomyopathy
ACM··········· arrhythmogenic cardiomyopathy
LMNA ········· lamin A and C
ECG ··········· electrocardiogram
CRT ··········· cardiac resynchronization therapy
ICD ············ implantable cardioverter–defibrillator
LINC ·········· linker of nucleoskeleton and cytoskeleton
LAD ··········· lamin-A-associated domain
HGPS ········· hutchinson-gilford progeria syndrome
MAPK ········· mitogen-activated protein kinase
mTOR ········ mammalian target of rapamycin
iPSCs ········· induced pluripotent stem cells
iCMs ·········· iPSC-derived cardiomyocytes
iCFs ··········· iPSC-derived cardiac fibroblasts
ERK ··········· extracellular signal-regulated kinase
AF ············· atrial fibrillation or flutter
VT ············· ventricular tachycardia
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VF ············· ventricular fibrillation
AV block ····· atrioventricular block
LBBB·········· left bundle branch block
PBMCs ······· peripheral mononuclear cells
CHF ··········· congestive heart failure
VA ············· ventricular arrhythmia
CCD ··········· cardiac conduction disease
SMD··········· skeletal muscle disease
AA ············· amino acid
LGE ··········· late gadolinium enhancement
MEA ··········· microelectrode array
FPDc ·········· corrected field potential duration
STAR ········· spliced transcripts alignment to a reference
FDR ··········· false discovery rate
TMM ·········· trimmed mean of M values
GO ············· gene ontology
BP ············· biological process
CC ············· cellular component
MF ············· molecular function
KEGG········· kyoto encyclopedia of genes and genomes
SCN5A ······· sodium voltage-gated channel alpha subunit 5
KCNH2 ······· potassium voltage-gated channel subfamily H member 2
KCNQ1 ······· potassium voltage-gated channel subfamily Q member 1
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ATP2A2 ······ sarcoplasmic/endoplasmic reticulum calcium-ATPase 2
PLN ··········· phospholamban
CASQ2 ······· calsequestrin 2
Cx43 ·········· connexin 43
GJA1 ·········· gap junction protein alpha 1
PCA ··········· principal component analysis
DEGs ········· differentially expressed genes
REAC ········· REACTOME
XIST··········· X-inactive specific transcript
CYP4F3 ······ cytochrome P450 family 4 subfamily F member 3
RPS4Y1 ······ ribosomal protein S4 Y-linked 1
PTN ··········· pleiotrophin
PBS ··········· phosphate buffered saline
ECM··········· extracellular matrix
UNC45B ····· UNC45 Myosin Chaperone B
MYOD1······· myoblast determination protein 1
MEG3 ········· maternally expressed gene 3
P2RY8 ········ P2Y Receptor Family Member 8
GJB2 ·········· gap junction beta-2 protein
ASNSP1 ····· asparagine synthetase-like 1
MMP ·········· matrix metalloproteinase
CV ············· conduction velocity
E-C delay ···· excitation contraction delay
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EAD ··········· early afterdepolarization
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